[{"shouldShowContactButton":true,"study":"Estonian Biobank","investigator":"Reedik Mägi","affiliation":"University of Tartu","country":"Estonia","city":"Tartu","studyLink":"https://genomics.ut.ee/en/access-biobank","retrospective":true,"prospective":true,"retrospectiveSampleSize":210000,"genotyping":true,"assaysPlanned":["Antibody profiling","Viral sequencing"],"researchQuestion":"Interested in QC and trans-ethnic meta-analysis of the main results. Our questionnaire also includes questions concerning anxiety and mental health due to virus outbreak.\n","studyDesign":"We plan to follow the analysis plan of this consortia. We will link laboratory testing data from EHR to find biobank participants who have been tested (both positive and negative). In parallel online questionnaire is being created and all tested people will be asked to fill it. Additionally we try to recruit new samples into biobank (who have been tested in lab for coronavirus). There are additional efforts starting in our university for antibody profiling and viral sequencing - we would link that data with our biobank samples if possible. \n","studyDesignUnformatted":"We plan to follow the analysis plan of this consortia. We will link laboratory testing data from EHR to find biobank participants who have been tested (both positive and negative). In parallel online questionnaire is being created and all tested people will be asked to fill it. Additionally we try to recruit new samples into biobank (who have been tested in lab for coronavirus). There are additional efforts starting in our university for antibody profiling and viral sequencing - we would link that data with our biobank samples if possible. ","timeCreated":1585474728000,"hasSubmittedData":true,"id":"recdbW7iyFIbcCWVl"},{"shouldShowContactButton":true,"study":"Netherlands Twin Register","investigator":"Eco de Geus, Michel Nivard, Meike Bartels, Dorret Boomsma","affiliation":"Vrije Universiteit Amsterdam","country":"Netherlands","city":"Amsterdam","studyLink":"https://tweelingenregister.vu.nl/","retrospective":true,"prospective":true,"retrospectiveSampleSize":10,"prospectiveSampleSize":30,"genotyping":true,"researchQuestion":"The goal of our study is to perform surveillance, via questionnaire, of Covid19 diagnosis & symptoms as well als the social/psychological response to lockdown conditions in a large cohort of genotyped. Dutch Twins in their family. The research question that flow form this are: \"What are the genetic determinants of Covid19 susceptibility?\" and \"What are the genetic determinants of wellbeing and mood in response to the lockdown situation in the Netherlands?\"\n","studyDesign":"We are trying to identify through record linkage which of the NTR participants that we have phenotypic information and whole-genome SNP genotyping on\n- have been tests for COVID-19 (and the outcome)\n- got sick (and how mild / severe their symptoms were)\n\nIn parallel we will send out (repeated) surveys to identify which of the participants that we have phenotypic information and whole-genome SNP genotyping on\n- have been tests for COVID-19 (and the outcome)\n- got sick (and how mild / severe their symptoms were)\nThese surevys will also record how people are affected by the coronacrisis in terms of mental health and health behaviors\n\n","studyDesignUnformatted":"We are trying to identify through record linkage which of the NTR participants that we have phenotypic information and whole-genome SNP genotyping on\n- have been tests for COVID-19 (and the outcome)\n- got sick (and how mild / severe their symptoms were)\n\nIn parallel we will send out (repeated) surveys to identify which of the participants that we have phenotypic information and whole-genome SNP genotyping on\n- have been tests for COVID-19 (and the outcome)\n- got sick (and how mild / severe their symptoms were)\nThese surevys will also record how people are affected by the coronacrisis in terms of mental health and health behaviors\n","timeCreated":1585488448000,"hasSubmittedData":true,"id":"reclvqFYoJYKcj6en"},{"shouldShowContactButton":true,"study":"Columbia University COVID19 Biobank","investigator":"Krzysztof Kiryluk, Wendy Chung, others","affiliation":"Columbia University","country":"United States","city":"New York","studyLink":"Pending","retrospective":true,"prospective":true,"prospectiveSampleSize":3000,"genotyping":true,"wes":true,"wgs":true,"assaysPlanned":["Transcriptomics","Viral sequencing","Immune profiling","Antibody profiling"],"otherAssays":"Collection planned, assays not yet funded: bulk blood RNA-seq, blood scRNA-seq, viral load (nasal), viral load (blood), anti-viral antibodies (blood), cytokine levels.\n","researchQuestion":"Our prospective study design consists of remote recruitment of all COVID+ patients across our Columbia/NYPH medical system. We have identified over 1,500 positive cases already, and the numbers are increasing very rapidly. We are tracking down and consenting all positive cases remotely, collect DNA, blood RNA, other bio specimens, administer electronic questionnaires (happy to share details) and extract EHR data to define outcomes.\n","studyDesign":"Case only design: \nOur biobank recruits only cases confirmed by a +COVID19 test. We are prioritizing within-case genetic analyses of various disease features and complications. This includes clinical metrics of disease severity (e.g. disease/fever duration, cytokine storm), and a complete list of disease complications (e.g. anosmia, PNA, myocarditis, kidney failure, respiratory failure, mortality). \nWe combine EHR data with a standardized electronic patient questionnaires to collect all outcome data (we are happy to share our data collection tools which incorporate questions from all existing tools that we found to date). \nAt minimum, all cases will undergo SNP typing, HLA imputation, & WES. Matching viral genome will also be sequenced if available. If there are funds, we may generate WGS and blood RNA-seq. We also have metabolomic and single cell RNA-seq capabilities.\nWe are IRB approved and actively recruiting. Given a very large number of cases in NYC, we anticipate to recruit well over 3,000 cases. Our participants are also consented for recontact, return of incidental genetic findings, and broad genetic/genomic data sharing.\n","researchCategory":["Disease severity","HLA"],"studyDesignUnformatted":"Case only design: \nOur biobank recruits only cases confirmed by a +COVID19 test. We are prioritizing within-case genetic analyses of various disease features and complications. This includes clinical metrics of disease severity (e.g. disease/fever duration, cytokine storm), and a complete list of disease complications (e.g. anosmia, PNA, myocarditis, kidney failure, respiratory failure, mortality). \nWe combine EHR data with a standardized electronic patient questionnaires to collect all outcome data (we are happy to share our data collection tools which incorporate questions from all existing tools that we found to date). \nAt minimum, all cases will undergo SNP typing, HLA imputation, & WES. Matching viral genome will also be sequenced if available. If there are funds, we may generate WGS and blood RNA-seq. We also have metabolomic and single cell RNA-seq capabilities.\nWe are IRB approved and actively recruiting. Given a very large number of cases in NYC, we anticipate to recruit well over 3,000 cases. Our participants are also consented for recontact, return of incidental genetic findings, and broad genetic/genomic data sharing.","timeCreated":1585488537000,"hasSubmittedData":true,"id":"recOTOX6c3DNl0Z7y"},{"shouldShowContactButton":true,"study":"Biobanque Quebec COVID19","investigator":"Brent Richards","affiliation":"McGill University","country":"Canada","city":"Montreal","prospective":true,"prospectiveSampleSize":30000,"genotyping":true,"wes":true,"assaysPlanned":["Transcriptomics","Proteomics","Metabolomics","Immune profiling"],"otherAssays":"We are planning for bronchial alveolar lavage on some study participants.\n","researchQuestion":"The main questions that we will investigate are:\n1) What are the predisposing factors for severity of infection (including omics profiling)?\n2) What the predisposing factors for intubation and duration of intubation (including omics profiling)?\n3) Are these factors different in individuals under the age of 65?\n","studyDesign":"This is a province-wide biobank of ~40,000 COVID19 tested individuals that is being collected prospectively. Inclusion criteria will be a COVID19 test at an emergency room in the province of Quebec. Individuals who are positive will be recruited, as well as a random selection of individuals who are negative.\nSamples will include: DNA, RNA, PBMCs, Plasma and Whole Blood. \nThis resource will be based upon open-science principles.\n","studyDesignUnformatted":"This is a province-wide biobank of ~40,000 COVID19 tested individuals that is being collected prospectively. Inclusion criteria will be a COVID19 test at an emergency room in the province of Quebec. Individuals who are positive will be recruited, as well as a random selection of individuals who are negative.\nSamples will include: DNA, RNA, PBMCs, Plasma and Whole Blood. \nThis resource will be based upon open-science principles.","timeCreated":1585488621000,"hasSubmittedData":true,"id":"recB6ySuGRYbFiBV3"},{"shouldShowContactButton":true,"study":"Genetic determinants of COVID-19 complications in the Brazilian population ","investigator":"Jose Krieger, Alexandre Pereira","affiliation":"Heart Institute, University of Sao Paulo","country":"Brazil","city":"Sao Paulo","prospective":true,"prospectiveSampleSize":1000,"genotyping":true,"assaysPlanned":["Antibody profiling"],"researchQuestion":"GWAS for disease severity comparing covid-19 patients that required mechanical ventilation (cases) with covid-19 patients that did not require mechanical ventilation (controls).\n","studyDesign":"Prospective study ascertaining individuals from the Sao Paulo city metropolitan area with a positive SARS-CoV-2 rna-based test. Baseline information on previous comorbidities, disease infection and presentation symptoms and follow-up information on clinical and mortality end-points will be collected.\n","studyDesignUnformatted":"Prospective study ascertaining individuals from the Sao Paulo city metropolitan area with a positive SARS-CoV-2 rna-based test. Baseline information on previous comorbidities, disease infection and presentation symptoms and follow-up information on clinical and mortality end-points will be collected.","timeCreated":1585496556000,"hasSubmittedData":true,"id":"rec8E8WgG0pKNq4Oj"},{"shouldShowContactButton":true,"study":"Genes & Health","investigator":"David van Heel","affiliation":"Queen Mary University of London","country":"United Kingdom","city":"London","studyLink":"www.genesandhealth.org","retrospective":true,"retrospectiveSampleSize":500,"genotyping":true,"researchQuestion":"Our main research interest is a very early GWAS of severe covid cases. To address the question: does host genetics influence why a few get very severe disease, whereas many get aysymptomatic or mild disease?\n","studyDesign":"28675 existing Illumina GSAv3EA+MD genotyped (post QC) volunteers of British south Asian ethnicity. 5000 of these also whole exome sequenced. We will identify which of these touch UK hospital systems in real time. Data will include inpatient status and health record collected clinical details, pathology (e.g. RT-qPCR and serology) etc.\n\nHigh rates of diabetes and ischaemic heart disease comorbidities. Estimate 2% of this population will be admitted to hospital. Thus 500 severe cases.\n","studyDesignUnformatted":"28675 existing Illumina GSAv3EA+MD genotyped (post QC) volunteers of British south Asian ethnicity. 5000 of these also whole exome sequenced. We will identify which of these touch UK hospital systems in real time. Data will include inpatient status and health record collected clinical details, pathology (e.g. RT-qPCR and serology) etc.\n\nHigh rates of diabetes and ischaemic heart disease comorbidities. Estimate 2% of this population will be admitted to hospital. Thus 500 severe cases.","timeCreated":1585500590000,"hasSubmittedData":true,"id":"receudmmbnVHHT8LQ"},{"shouldShowContactButton":true,"study":"Lifelines","investigator":"Lude Franke","affiliation":"University Medical Centre Groningen","country":"Netherlands","city":"Groningen","studyLink":"www.lifelines.nl","retrospective":true,"retrospectiveSampleSize":5000,"genotyping":true,"wes":true,"assaysPlanned":["Transcriptomics","Viral sequencing","Proteomics","Metabolomics","Antibody profiling","Immune profiling"],"otherAssays":"scRNA-seq in PBMCs\n","researchQuestion":"Lifelines is a longitudinal biobank that has been following 167,000 individuals for over 10 years. Lifelines has repeated measurements of a large number of phenotypes and biomarkers and also has questionnaires at different times points. We are currently sending out weekly questionnaires to ask people about their health, wellbeing and social economic status. Here we also ask if they have been tested for COVID19. We want to contribute to the COVID19 GWAS studies, test how past health problems, drug usage, and environmental factors influence COVID19 susceptibility and severity. We will also study the effect of the pandemic on people's wellbeing and psychological health.\n","studyDesign":"Lifelines is a prospective population based biobank, comprising in total 167,000 individuals, living in the Northern Netherlands. We are sending out weekly questionnaires, asking for COVID-19 related symptoms. We are working to link clinically proven COVID-19 infection status to our biobank, such the we can perform a GWAS on COVID-19 severity.\n","studyDesignUnformatted":"Lifelines is a prospective population based biobank, comprising in total 167,000 individuals, living in the Northern Netherlands. We are sending out weekly questionnaires, asking for COVID-19 related symptoms. We are working to link clinically proven COVID-19 infection status to our biobank, such the we can perform a GWAS on COVID-19 severity.","timeCreated":1585505867000,"hasSubmittedData":true,"id":"reccNMPbCZCZVIgyy"},{"shouldShowContactButton":true,"study":"COVID-19 Host Immune Response Pathogenesis (CHIRP) Study","investigator":"Sulggi Lee, MD PHD","affiliation":"University of California San Francisco","country":"United States","city":"San Francisco","studyLink":"https://sulggileelab.ucsf.edu/","retrospective":true,"prospective":true,"retrospectiveSampleSize":8000,"prospectiveSampleSize":60,"wes":true,"assaysPlanned":["Viral sequencing","Transcriptomics","Immune profiling"],"otherAssays":"Serology, Host-human interactome profiling, COVID-specific B and T cell responses, Microbiome\n","researchQuestion":"The overall objective of this study is to determine the host genetic, immunologic, virologic, clinical, demographic, and behavioral factors associated with COVID-19 susceptibility and severity of disease.\n","studyDesign":"1. Nested case-control from retrospective CNIC cohort (<https://www.uab.edu/cnics/>)\n2. Prospective cohort\n3. Interventional studies (will have opportunity to expand upon #2 above)\n","studyDesignUnformatted":"1. Nested case-control from retrospective CNIC cohort (https://www.uab.edu/cnics/)\n2. Prospective cohort\n3. Interventional studies (will have opportunity to expand upon #2 above)","timeCreated":1585516540000,"hasSubmittedData":false,"id":"rec61w6huaj9sotDz"},{"shouldShowContactButton":true,"study":"UK 100,000 Genomes Project","investigator":"Mark Caulfield, Richard Scott, Tom Fowler, Augusto Rendon","affiliation":"Genomics England","country":"United Kingdom","city":"London","studyLink":"www.genomicsengland.co.uk","wgs":true,"researchQuestion":"The 100,000 Genomes Project (100KGP) was launched in 2013 to apply whole genome sequencing (WGS) to rare disease, cancer and infection in national healthcare in the UK. It contains over 100,000 high coverage whole genomes from around 85,000 NHS patients. Analyses contributed to the COVID-19 HGI are based on SARS-COV-2 status and other clinical and phenotypic information available for these participants.\n","studyDesign":"The 100KGP includes NHS patients with rare diseases, and their families, as well as patients with common cancers. All participants have high coverage WGS data available and are linked to electronic health records. Covid-19 test results are obtained from Public Health England. More information on the 100KGP can be found at <https://www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project/>\n","studyDesignUnformatted":"The 100KGP includes NHS patients with rare diseases, and their families, as well as patients with common cancers. All participants have high coverage WGS data available and are linked to electronic health records. Covid-19 test results are obtained from Public Health England. More information on the 100KGP can be found at https://www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project/","timeCreated":1585570671000,"hasSubmittedData":true,"id":"recNyFjIvagWavCOf"},{"shouldShowContactButton":true,"study":"Finngen","investigator":"Andrea Ganna, Mark Daly","affiliation":"Institute for Molecular Medicine Finland","country":"Finland","city":"Helsinki","studyLink":"https://www.finngen.fi/en","retrospective":true,"retrospectiveSampleSize":250000,"genotyping":true,"researchQuestion":"We are mostly interested in exploring the genetic determinants of COVID19 susceptibility and severity. COVID19 cases are obtained from the infection register. In-patient and outpatient registers will be use to evaluate comorbidities. \n","studyDesign":"Biobank-based study, will connect Finngen with the infection registry to obtain information on patients diagnosed with COVID-19.\n","studyDesignUnformatted":"Biobank-based study, will connect Finngen with the infection registry to obtain information on patients diagnosed with COVID-19.","timeCreated":1585572458000,"hasSubmittedData":true,"id":"rec5z4bwwG70xjd1l"},{"shouldShowContactButton":true,"study":"Genomic epidemiology of SARS-Cov-2 and host genetics in Coronavirus Disease 2019 (COVID-19)","investigator":"Manuel Rivas, Euan Ashley, Carlos Bustamante, Ben Pinsky","affiliation":"Stanford University","country":"United States","city":"Stanford","retrospective":true,"prospective":true,"retrospectiveSampleSize":100,"prospectiveSampleSize":100,"wgs":true,"assaysPlanned":["Viral sequencing","Antibody profiling","Immune profiling"],"researchQuestion":" The study is designed to characterize the genomic epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS coronavirus 2, or SARS-CoV-2) and define host genetic effects on the outcome of viral infection.\n","studyDesign":"Viral and host genome sequencing.\n","researchCategory":["Disease severity","Viral sequencing"],"studyDesignUnformatted":"Viral and host genome sequencing.","timeCreated":1585587143000,"hasSubmittedData":true,"id":"recRNR9gim97aAdPI"},{"shouldShowContactButton":true,"study":"University of Utah Genomic Signal Processing Lab","investigator":"Orly Alter","affiliation":"University of Utah","country":"United States","city":"Salt Lake City","studyLink":"https://alterlab.org/","wgs":true,"researchQuestion":"Multi-Tensor Decompositions for Personalized Coronavirus Infection Prognostics, Diagnostics, and Therapeutics\n","studyDesign":"Using our mathematical methods, which are uniquely successful at discovering clinically actionable genotype-phenotype relationships in whole genomes of small cohorts of patients (order of magnitude of 100), on such data as viral sequences and patient whole genomes with de-identified patient clinical information. The relationships can improve the prognostics, diagnostics, and therapeutics of the disease. A recent glioblastoma brain cancer retrospective clinical trial provides a proof of principle of the mathematical methods.\n","studyDesignUnformatted":"Using our mathematical methods, which are uniquely successful at discovering clinically actionable genotype-phenotype relationships in whole genomes of small cohorts of patients (order of magnitude of 100), on such data as viral sequences and patient whole genomes with de-identified patient clinical information. The relationships can improve the prognostics, diagnostics, and therapeutics of the disease. A recent glioblastoma brain cancer retrospective clinical trial provides a proof of principle of the mathematical methods.","timeCreated":1585589840000,"hasSubmittedData":false,"id":"recS4PcQuN0oaGvyT"},{"shouldShowContactButton":true,"study":"Genotek COVID-19 study","investigator":"Alexandr Rakitko, Artem Elmuratov, Valery Ilinsky","affiliation":"Genotek Ltd.","country":"Russia","city":"Moscow","prospective":true,"prospectiveSampleSize":10000,"genotyping":true,"researchQuestion":"We are interested in the development of the polygenic risk score to predict the   COVID-19 susceptibility, severity and outcomes.\n","studyDesign":"Genotek is a DNA testing company like 23andme, ftDNA etc. We operate in Russia and have our own lab in Moscow. We plan to offer the COVID-2019 tests for our current and future clients. So we collect the genotype data (Global Screening Array v3) for both cases and controls. \n","researchCategory":["Disease severity","Disease susceptibility"],"studyDesignUnformatted":"Genotek is a DNA testing company like 23andme, ftDNA etc. We operate in Russia and have our own lab in Moscow. We plan to offer the COVID-2019 tests for our current and future clients. So we collect the genotype data (Global Screening Array v3) for both cases and controls. ","timeCreated":1585591018000,"hasSubmittedData":true,"id":"recHK91fVsv3ATVK4"},{"shouldShowContactButton":true,"study":"BioVU","investigator":"Nancy Cox, Jennnifer \"Piper\" Below, Lea Davis, Simon Mallal, Elizabeth Phillips","affiliation":"Vanderbilt University Medical Center","country":"United States","city":"Nashville","studyLink":"https://victr.vumc.org/what-is-biovu/","retrospective":true,"retrospectiveSampleSize":2500,"genotyping":true,"otherAssays":"Phenome-wide/lab-wide/EHR based analyses\n","researchQuestion":"Epidemiological and genetic investigations into COVID19 risk and outcomes.\n","studyDesign":"Case/control and labs-based GWAS, age/sex/comorbidity stratified analyses, pharmacogenomics, polygenic risk assessments, severity analyses\n","researchCategory":["Disease severity"],"studyDesignUnformatted":"Case/control and labs-based GWAS, age/sex/comorbidity stratified analyses, pharmacogenomics, polygenic risk assessments, severity analyses","timeCreated":1585594373000,"hasSubmittedData":true,"id":"reczGoLEjfkkRVcwH"},{"shouldShowContactButton":true,"study":"HUNT","investigator":"Cristen Willer, Kristian Hveem","affiliation":"NTNU in Norway, University of Michigan","country":"Norway","city":"Trondheim","retrospective":true,"retrospectiveSampleSize":100,"genotyping":true,"researchQuestion":"Host genetics related to severity following SARS-COV2 infection\n","studyDesign":"GWAS using severity as a quantitative trait \n","researchCategory":["Disease severity"],"studyDesignUnformatted":"GWAS using severity as a quantitative trait ","timeCreated":1585596522000,"hasSubmittedData":true,"id":"recQPEKCeBBkoaPkt"},{"shouldShowContactButton":true,"study":"Rotterdam Study","investigator":"Andre G Uitterlinden, Fernando Rivadeneira, Joyce Van Meurs, Arfan Ikram, Carolina Medina","affiliation":"ErasmusMC","country":"Netherlands","city":"Rotterdam","studyLink":"www.erasmus-epidemiology.nl/rotterdamstudy","retrospective":true,"retrospectiveSampleSize":14000,"genotyping":true,"wes":true,"assaysPlanned":["Metabolomics","Transcriptomics"],"researchQuestion":"COVID-19 genetic susceptibility, other risk factors affecting COVID-19 outcome and response to treatment\n","studyDesign":"The Rotterdam Study is a prospective cohort study ongoing since 1990 in the city of Rotterdam in The Netherlands. The study targets cardiovascular, endocrine, hepatic, neurological, ophthalmic, psychiatric, dermatological, otolaryngological, locomotor, and respiratory diseases. As of 2008, 14,926 subjects aged 45 years or over comprise the Rotterdam Study cohort. Since 2016, the cohort is being expanded by persons aged 40 years and over. The findings of the Rotterdam Study have been presented in over 1500 research articles and reports\n","researchCategory":["Disease severity","Disease susceptibility"],"studyDesignUnformatted":"The Rotterdam Study is a prospective cohort study ongoing since 1990 in the city of Rotterdam in The Netherlands. The study targets cardiovascular, endocrine, hepatic, neurological, ophthalmic, psychiatric, dermatological, otolaryngological, locomotor, and respiratory diseases. As of 2008, 14,926 subjects aged 45 years or over comprise the Rotterdam Study cohort. Since 2016, the cohort is being expanded by persons aged 40 years and over. The findings of the Rotterdam Study have been presented in over 1500 research articles and reports","timeCreated":1585649225000,"hasSubmittedData":true,"id":"recshOAksol9dMKFF"},{"shouldShowContactButton":true,"study":"The Generation R study","investigator":"Andre G. Uitterlinden, Fernando Rivadeneira, Janine Felix, Vincent Jaaddoe, Carolina Medina-Gomez","affiliation":"ErasmusMC","country":"The Netherlands","city":"Rotterdam","retrospective":true,"retrospectiveSampleSize":9000,"genotyping":true,"wes":true,"assaysPlanned":["Metabolomics"],"otherAssays":"Microbiome 16S\n","researchQuestion":"Genetic and epidemiological factors affecting acquisition and progression COVID19 in pediatric populations\n","studyDesign":"The Generation R Study is a population-based prospective cohort study from fetal life until adulthood. The study is designed to identify early environmental and genetic causes and causal pathways leading to normal and abnormal growth, development and health during fetal life, childhood and adulthood. The study focuses on six areas of research: (1) maternal health; (2) growth and physical development; (3) behavioural and cognitive development; (4) respiratory health and allergies; (5) diseases in childhood; and (6) health and healthcare for children and their parents. Main exposures of interest include environmental, endocrine, genetic and epigenetic, lifestyle related, nutritional and socio-demographic determinants. In total, n = 9,778 mothers with a delivery date from April 2002 until January 2006 were enrolled in the study. Response at baseline was 61 %, and general follow-up rates until the age of 6 years exceed 80 %. Data collection in mothers, fathers and children include questionnaires, detailed physical and ultrasound examinations, behavioural observations, and biological samples. A genome and epigenome wide association screen is available in the participating children. From the age of 5 years, regular detailed hands-on assessments are performed in a dedicated research center including advanced imaging facilities such as Magnetic Resonance Imaging. Eventually, results forthcoming from the Generation R Study contribute to the development of strategies for optimizing health and healthcare for pregnant women and children.\n","researchCategory":["Pediatrics"],"studyDesignUnformatted":"The Generation R Study is a population-based prospective cohort study from fetal life until adulthood. The study is designed to identify early environmental and genetic causes and causal pathways leading to normal and abnormal growth, development and health during fetal life, childhood and adulthood. The study focuses on six areas of research: (1) maternal health; (2) growth and physical development; (3) behavioural and cognitive development; (4) respiratory health and allergies; (5) diseases in childhood; and (6) health and healthcare for children and their parents. Main exposures of interest include environmental, endocrine, genetic and epigenetic, lifestyle related, nutritional and socio-demographic determinants. In total, n = 9,778 mothers with a delivery date from April 2002 until January 2006 were enrolled in the study. Response at baseline was 61 %, and general follow-up rates until the age of 6 years exceed 80 %. Data collection in mothers, fathers and children include questionnaires, detailed physical and ultrasound examinations, behavioural observations, and biological samples. A genome and epigenome wide association screen is available in the participating children. From the age of 5 years, regular detailed hands-on assessments are performed in a dedicated research center including advanced imaging facilities such as Magnetic Resonance Imaging. Eventually, results forthcoming from the Generation R Study contribute to the development of strategies for optimizing health and healthcare for pregnant women and children.","timeCreated":1585649511000,"hasSubmittedData":false,"id":"recdFXVPsxlji3GzK"},{"shouldShowContactButton":true,"study":"Amsterdam UMC COVID study group","investigator":"Diederik van de Beek, Matthijs Brouwer, Joost Wiersinga, Alexander Vlaar, Danielle Postuma","affiliation":"Amsterdam University Medical Centers, University of Amsterdam","country":"Netherlands","city":"Amsterdam","prospective":true,"prospectiveSampleSize":2000,"researchQuestion":"What are the determinants of susceptibility, severity and outcome of COVID-19\n","studyDesign":"The Amsterdam UMC COVID study group prospectively collects clinical and radiological data, outcome data, DNA, swabs, serial blood samples and immune cells of all patients with COVID-19 in Amsterdam UMC. \n","researchCategory":["Disease severity","Disease susceptibility"],"studyDesignUnformatted":"The Amsterdam UMC COVID study group prospectively collects clinical and radiological data, outcome data, DNA, swabs, serial blood samples and immune cells of all patients with COVID-19 in Amsterdam UMC. ","timeCreated":1585658213000,"hasSubmittedData":true,"id":"recMnOUGOqTejvyXv"},{"shouldShowContactButton":true,"study":"MSKCC","investigator":"Kelly Bolton, Ken Offit, Vijai Joseph","affiliation":"Memorial Sloan Kettering","country":"United States","city":"New York","retrospective":true,"prospective":true,"retrospectiveSampleSize":1000,"genotyping":true,"wes":true,"researchQuestion":"Impact of host genomics and clonal hematopoiesis on disease severity\n","studyDesign":"Patients at MSK with COVID-19 infection who had blood samples banked through several bio-specimen protocols. We are also seeking to establish a prospective study including bio-specimens and questionnaire data among COVID-19 infected patients at MSK. \n","researchCategory":["Disease severity"],"studyDesignUnformatted":"Patients at MSK with COVID-19 infection who had blood samples banked through several bio-specimen protocols. We are also seeking to establish a prospective study including bio-specimens and questionnaire data among COVID-19 infected patients at MSK. ","timeCreated":1585672857000,"hasSubmittedData":false,"id":"recJBWI9dg0GmQYG9"},{"shouldShowContactButton":true,"study":"CHRIS","investigator":"Cristian Pattaro, Christian Fuchsberger","affiliation":"Eurac Research, Institute for Biomedicine","country":"Italy","city":"Bolzano","retrospective":true,"prospective":true,"genotyping":true,"wes":true,"researchQuestion":"   \n","studyDesign":"  \n","studyDesignUnformatted":"  ","timeCreated":1585680442000,"hasSubmittedData":true,"id":"recwxA0kisVlVrtiE"},{"shouldShowContactButton":true,"study":"Genetics of host resistance to COVID-19","investigator":"Jamal Nasir, Nirmal Vadgama, Augustus Lusack","affiliation":"University of Northampton","country":"United Kingdom","city":"Northampton","retrospective":true,"prospective":true,"retrospectiveSampleSize":100,"prospectiveSampleSize":100,"genotyping":true,"wes":true,"otherAssays":"\n","researchQuestion":"The COVID-19 pandemic has posed many challenges. Many questions remain unanswered. With more than a million deaths worldwide and still growing, the pathology remains a puzzle. The widely varying clinical presentation, rates of disease progression, and outcomes, suggest multiple and complex disease causing mechanisms. Furthermore, the highest rates of infection correlate significantly with ethnicity, gender, age, and comorbidities, including diabetes and cardiovascular disease. The receptor binding domain (RBD) of the spike protein (S) of SARS-CoV-2 binds ACE2 (a cell surface receptor present on many cell types), in order to gain entry into the cell, and it is widely expected host genetics is likely to play a role in the pathogenesis of COVID-19.\nThe overarching aim of this project is to gain insights into the role of host genetics in COVID-19. We are interested in 1) GWAS and candidate gene studies; 2) exome and whole genome sequencing; 3) structural variants; 4) methylation; 5) RNA seq; 6) Omics; 7) molecular modelling and related approaches to identify relevant SNPs or other genetic variants involved in COVID-19. One of our main areas of interest includes HLA, immunity and interferon related signalling pathways.\n","studyDesign":"We will undertake bioinformatics approaches to address the key questions outlined above. Our research aims to uncover he underlying genetics of immune response and host susceptibility as a first step towards a better understanding of the underlying pathophysiology of COVID-19. Separately, we will analyse proteomics data and undertake pathway analysis. Ultimately, we are also aiming to undertake experimental approaches, including _in vitro_ studies, in order to further validate our findings.\n","researchCategory":["Disease severity"],"studyDesignUnformatted":"We will undertake bioinformatics approaches to address the key questions outlined above. Our research aims to uncover he underlying genetics of immune response and host susceptibility as a first step towards a better understanding of the underlying pathophysiology of COVID-19. Separately, we will analyse proteomics data and undertake pathway analysis. Ultimately, we are also aiming to undertake experimental approaches, including in vitro studies, in order to further validate our findings.","timeCreated":1585684702000,"hasSubmittedData":false,"id":"rec0hiPBLm6tWoBvq"},{"shouldShowContactButton":true,"study":"The genetic predisposition to severe COVID-19","investigator":"Hugo Zeberg","affiliation":"Karolinska Institutet","country":"Sweden","city":"Stockholm","prospective":true,"prospectiveSampleSize":1000,"genotyping":true,"otherAssays":"Targeted sequencing (e.g. AmpliSeq). \n","researchQuestion":"The genetic susceptibility of severe COVID-19 in general and the influence of qQTL for the course of the disease in particular. \n","studyDesign":"PCR-verfied COVID-19 patient requiring hospitalization, at different levels of care (ICU vs  acute ward care). Genotyping at SciLifeLab using Illumina GSA-MD array. In addition to genotyping also targeted sequencing with AmpliSeq (or equivalent method). We plan to test some hypothesis locally and in addtition follow the protocol set up by the intiatitive for the GWAS meta-analysis.\n","researchCategory":["Disease severity"],"studyDesignUnformatted":"PCR-verfied COVID-19 patient requiring hospitalization, at different levels of care (ICU vs  acute ward care). Genotyping at SciLifeLab using Illumina GSA-MD array. In addition to genotyping also targeted sequencing with AmpliSeq (or equivalent method). We plan to test some hypothesis locally and in addtition follow the protocol set up by the intiatitive for the GWAS meta-analysis.","timeCreated":1585684787000,"hasSubmittedData":true,"id":"recTDRnNzz3tsmrqY"},{"shouldShowContactButton":true,"study":"GenOMICC (Genetics Of Mortality in Critical Care)","investigator":"A global consortium of critical care clincians","affiliation":"University of Edinburgh","country":"United Kingdom","city":"Edinburgh","studyLink":"https://genomicc.org","prospective":true,"prospectiveSampleSize":10000,"genotyping":true,"wgs":true,"assaysPlanned":["Transcriptomics","Antibody profiling","Immune profiling","Proteomics","Viral sequencing"],"researchQuestion":"GenOMICC is an open global consortium of critical care clinicians studying genetics of susecptibility to critical illness with COVID-19 and other conditions\t\n","studyDesign":"Primary analysis is critically ill (intubated) cases vs population controls\n","researchCategory":["Disease severity"],"studyDesignUnformatted":"Primary analysis is critically ill (intubated) cases vs population controls","timeCreated":1585685055000,"hasSubmittedData":true,"id":"rec9njQoJfhzLTCZC"},{"shouldShowContactButton":true,"study":"Mass General Brigham - Host Vulnerability to COVID-19","investigator":"Robert Green, Jordan Smoller, Beth Karlson, Scott Weiss, Shawn Murphy, Pradeep Natarajan, James Meigs, Ann Woolley","affiliation":"Mass General Brigham Biobank, Broad Institute, Harvard Medical School","country":"United States","city":"Boston","retrospective":true,"prospective":true,"genotyping":true,"wes":true,"wgs":true,"researchQuestion":"Starting with simple questions about genomic markers for severity of phenotype.  Will coordinate in real time with many multi-omics and immune investigators simultaneously using the Mass General Brigham Biobank.\n","studyDesign":"Under development.  We may or may not have enough genotyped and/or sequenced cases for independent analyses but very much want to contribute to the sample sizes needed for analyses in combination with others.\n","researchCategory":["Disease severity"],"studyDesignUnformatted":"Under development.  We may or may not have enough genotyped and/or sequenced cases for independent analyses but very much want to contribute to the sample sizes needed for analyses in combination with others.","timeCreated":1585689965000,"hasSubmittedData":true,"id":"recf90MMUzSNDmBb4"},{"shouldShowContactButton":true,"study":"GCAT. Genomes For Life. ","investigator":"Rafael de Cid, Lauro Sumoy, Mario Cáceres, Iván Galván-Femenía, Victor Moreno, Anna Carreras, Natalia Blay, Xavier Farré, Manolis Kogevinas (on behalf of the COVICAT study)","affiliation":"Genomes for Life- GCAT lab Germans Trias i Pujol Research Institute (IGTP)","country":"Spain","city":"Badalona","studyLink":"www.genomesforlife.org","retrospective":true,"prospective":true,"retrospectiveSampleSize":20000,"prospectiveSampleSize":5000,"genotyping":true,"assaysPlanned":["Antibody profiling"],"researchQuestion":"1) Prevalence of COVID-19 in the general population \n2) Host genetics in susceptibility and prognosis \n3) Mental health, social and environmental impact \n4) Morbidity in susceptibility and prognosis \n","studyDesign":"GCAT cohort is a adult (40-66) population based cohort linked to EHR from Catalan National Health System. GCAT links laboratory and clinical data from with all GCAT Cohort participants: SARS-Cov2 molecular testing, severity parameters, comorbidity are regularly updated. Lifestyle and exposome is linked with the cohort (pre-pandemic baseline info and regular follow up) and post-outbreak by an specific SarsCov-2 prospective survey, the COVICAT study. This study integrate biannual extended survey from may 2020, combined with frequent weekly-dayly reports based on wereables and e-App. Serology typing (IgM, IgG, IgA) is perfomed to evaluate prevalence and inmune response to COVID-19.\n","researchCategory":["Disease severity","Disease susceptibility"],"studyDesignUnformatted":"GCAT cohort is a adult (40-66) population based cohort linked to EHR from Catalan National Health System. GCAT links laboratory and clinical data from with all GCAT Cohort participants: SARS-Cov2 molecular testing, severity parameters, comorbidity are regularly updated. Lifestyle and exposome is linked with the cohort (pre-pandemic baseline info and regular follow up) and post-outbreak by an specific SarsCov-2 prospective survey, the COVICAT study. This study integrate biannual extended survey from may 2020, combined with frequent weekly-dayly reports based on wereables and e-App. Serology typing (IgM, IgG, IgA) is perfomed to evaluate prevalence and inmune response to COVID-19.","timeCreated":1585740963000,"hasSubmittedData":true,"id":"rec0ytN125bHe8OVH"},{"shouldShowContactButton":true,"study":"UCLA Precision Health COVID-19 Biobank ","investigator":"Dan Geschwind,  Nelson Freimer, Bogdan Pasaniuc,","affiliation":"UCLA","country":"United States","city":"Los Angeles","studyLink":"https://www.uclahealth.org/precision-health/","retrospective":true,"prospective":true,"retrospectiveSampleSize":1000,"prospectiveSampleSize":1000,"genotyping":true,"wes":true,"assaysPlanned":["Antibody profiling","Immune profiling"],"researchQuestion":"The impact of genome variation, ancestry and other relevant EHR features in COVID-19 susceptibility, severity, improved therapeutics and prevention strategies.\n","studyDesign":"We will biobank COVID-19 individuals from UCLA health system and collect detailed phenotypic and genotypic information. Together with existing EHR-linked genotype data from UCLA IPH Biobank (ATLAS, 150k) will be used to perform genetic association analyses to elucidate the role of common/rare variation in COVID-19 susceptibility and severity. The EHR data of ~2M patient records will be mined to identify risk novel risk factors and in estimating the effect of known factors such as age, sex and genetic ancestry. We will investigate the role of HLA types in risk in conjunction with virus genomes. \n","researchCategory":["Disease severity","Disease susceptibility","Therapeutics","Prevention","HLA"],"studyDesignUnformatted":"We will biobank COVID-19 individuals from UCLA health system and collect detailed phenotypic and genotypic information. Together with existing EHR-linked genotype data from UCLA IPH Biobank (ATLAS, 150k) will be used to perform genetic association analyses to elucidate the role of common/rare variation in COVID-19 susceptibility and severity. The EHR data of ~2M patient records will be mined to identify risk novel risk factors and in estimating the effect of known factors such as age, sex and genetic ancestry. We will investigate the role of HLA types in risk in conjunction with virus genomes. ","timeCreated":1585763353000,"hasSubmittedData":true,"id":"recBOqj5VjGgcFCw3"},{"shouldShowContactButton":true,"study":"The FVG COVID-19 Project","investigator":"Paolo Gasparini, Giorgia Girotto, Massimiliano Cocca, Margherita Francescatto","affiliation":"Department of Medical, Surgical and Health Sciences, University of Trieste/Institute for Maternal and Child Health, IRCCS Burlo Garofolo","country":"Italy","city":"Trieste","prospective":true,"prospectiveSampleSize":750,"genotyping":true,"wes":true,"assaysPlanned":["Antibody profiling","Immune profiling"],"researchQuestion":"Identify genetic and immune biomarkers involved in COVID-19 susceptibility and disease outcome\n","studyDesign":"At least 700 participants will be recruited among the employees of the IRCCS “Burlo Garofolo” Hospital of Trieste. Basic information will be collected through a first questionnaire and detailed anamnestic information will be added with a follow up, integrated with EHRs where available. SNParray gentotyping will be performed on all samples collected. Additionally phenotype and genotype (WES/WGS) data from at least 50 patients hospitalized in Trieste will be collected.\n","researchCategory":["Disease severity","Disease susceptibility","Immunologic response"],"studyDesignUnformatted":"At least 700 participants will be recruited among the employees of the IRCCS “Burlo Garofolo” Hospital of Trieste. Basic information will be collected through a first questionnaire and detailed anamnestic information will be added with a follow up, integrated with EHRs where available. SNParray gentotyping will be performed on all samples collected. Additionally phenotype and genotype (WES/WGS) data from at least 50 patients hospitalized in Trieste will be collected.","timeCreated":1585823907000,"hasSubmittedData":false,"id":"rec7tgfKJy5XOXOWk"},{"shouldShowContactButton":true,"study":"Variability in immune response genes and severity of SARS-CoV-2 infection (INMUNGEN-CoV2 study)","investigator":"Planas AM, Fernandez-Cadenas I, Perez-Tur J, Lozano F, Mensa A, Mensa J","affiliation":"IIBB-CSIC","country":"Spain","city":"Barcelona","prospective":true,"prospectiveSampleSize":400,"genotyping":true,"wes":true,"assaysPlanned":["Transcriptomics"],"otherAssays":"\n","researchQuestion":"The objective is to find out why some individuals are more vulnerable than others to SARS-CoV-2 infection. The findings will allow identifying patients at risk of developing severe COVID-19.\n","studyDesign":"Study genetic variants in SARS-CoV-2 patients (PCR+) from Hospital Clinic of Barcelona comparing patients with mild versus severe symptoms (n=200).\nInclusion: women and men less than 60 years old, devoid of chronic pathology. Validation in additional n=200 patients.\nStudies: Axiom Spain Biobank Array and WES analysis.  Data will be included in a larger GWAS initiative in Spain. In a subgroup of patients we will perform transcriptomic analysis.\n","researchCategory":["Disease severity"],"studyDesignUnformatted":"Study genetic variants in SARS-CoV-2 patients (PCR+) from Hospital Clinic of Barcelona comparing patients with mild versus severe symptoms (n=200).\nInclusion: women and men less than 60 years old, devoid of chronic pathology. Validation in additional n=200 patients.\nStudies: Axiom Spain Biobank Array and WES analysis.  Data will be included in a larger GWAS initiative in Spain. In a subgroup of patients we will perform transcriptomic analysis.","timeCreated":1585855278000,"hasSubmittedData":true,"id":"recw6yBER9ollv7S3"},{"shouldShowContactButton":true,"study":"The Norwegian Mother, Father and Child Cohort Study","investigator":"Øyvind Helgeland, Per Magnus, Gun Peggy Knudsen","affiliation":"Norwegian Institute of Public Health","country":"Norway","city":"Oslo","studyLink":"https://www.fhi.no/en/studies/moba/","retrospective":true,"retrospectiveSampleSize":500,"genotyping":true,"researchQuestion":"Host genetics associated with severity of COVID19 infection\n","studyDesign":"GWAS using severity as a quantitative trait\n","researchCategory":["Disease severity"],"studyDesignUnformatted":"GWAS using severity as a quantitative trait","timeCreated":1585910898000,"hasSubmittedData":true,"id":"recNFuBg1PTxAhNWr"},{"shouldShowContactButton":true,"study":"French hgCOVID","investigator":"Hugues Aschard, Anavaj Sakuntabhai, Stephanie Debette, Lluis Quintana-Murci","affiliation":"Institut Pasteur","country":"France","city":"Paris","studyLink":"tbd","retrospective":true,"prospective":true,"prospectiveSampleSize":1000,"genotyping":true,"assaysPlanned":["Transcriptomics","Immune profiling","Proteomics"],"otherAssays":"TBD - additional assay might be available\n","researchQuestion":"Human genetic basis of immunological responses to SARS-CoV-2\n","studyDesign":"The collection will include participants from multiple ongoing prospective studies in France recruiting both COVID cases and contact cases. It might also inlcude participants from existing population based studies to be used as controls.\n","researchCategory":["Disease severity","Immunologic response"],"studyDesignUnformatted":"The collection will include participants from multiple ongoing prospective studies in France recruiting both COVID cases and contact cases. It might also inlcude participants from existing population based studies to be used as controls.","timeCreated":1585931368000,"hasSubmittedData":false,"id":"recqqppM9EWbGEJjS"},{"shouldShowContactButton":true,"study":"GEN-COVID, reCOVID","investigator":"Alessandra Renieri","affiliation":"University of Siena","country":"Italy","city":"Siena","studyLink":"https://sites.google.com/dbm.unisi.it/gen-covid","retrospective":true,"prospective":true,"retrospectiveSampleSize":1000,"prospectiveSampleSize":2000,"genotyping":true,"wes":true,"assaysPlanned":["Viral sequencing","Antibody profiling","Immune profiling"],"researchQuestion":"The primary aim of this project is to compare the genetic profile of laboratory-confirmed COVID-19 patients with mild _vs_ severe symptoms. In secondary analysis we will compare all infected patients with a population control sample, incorporate immunoglobulin G response in the phenotype definition, and evaluate how the genetic profile is associated with patient outcomes\n","studyDesign":"UNISI We will extract DNA on at least 2,000 samples from COVID-19 patients collected across Italy. Samples we will ship to the Institute for Molecular Medicine Finland (FIMM).  FIMM will genotype the individuals using a SNP array (Illumina Global Screening Array (GSA)) and perform quality control and association analyses. An HLA-specific imputation panel for the population will be used to obtain better coverage of HLA alleles. The DNA samples will be used by FIMM for GWAS analysis only. Any leftover has to be send back to UNISI. UNISI will perform whole exome sequencing.\n","researchCategory":["Disease severity","Immunologic response","HLA"],"studyDesignUnformatted":"UNISI We will extract DNA on at least 2,000 samples from COVID-19 patients collected across Italy. Samples we will ship to the Institute for Molecular Medicine Finland (FIMM).  FIMM will genotype the individuals using a SNP array (Illumina Global Screening Array (GSA)) and perform quality control and association analyses. An HLA-specific imputation panel for the population will be used to obtain better coverage of HLA alleles. The DNA samples will be used by FIMM for GWAS analysis only. Any leftover has to be send back to UNISI. UNISI will perform whole exome sequencing.","timeCreated":1585938754000,"hasSubmittedData":true,"id":"recXKfjqGpf7c7ayu"},{"shouldShowContactButton":true,"study":"Penn Medicine Biobank","investigator":"Daniel Rader, Marylyn Ritchie","affiliation":"University of Pennsylvania","country":"United States","city":"Philadelphia","retrospective":true,"prospective":true,"retrospectiveSampleSize":2000,"prospectiveSampleSize":3000,"genotyping":true,"wes":true,"assaysPlanned":["Immune profiling","Antibody profiling","Transcriptomics","Proteomics","Metabolomics"],"researchQuestion":"Common and rare host genetic variants that predispose to or protect against symptomatic SARS-CoV-2 infection and adverse clinical outcomes.\nAssociation of genetic variation with SARS-CoV-2 seroconversion. \n","studyDesign":"We have an existing Penn Medicine Biobank of ~60,000 participants consented for genetic studies and EHR data and are actively following up these individuals for those who get infected with SARS-CoV-2.\nWe are prospectively consenting and obtaining DNA from COVID-19 inpatients from Penn Medicine hospitals and contemporaneous inpatient controls.\nWe are prospectively recruiting outpatients with a confirmed diagnosis of COVID-19 and controls who were tested by nasal swab and confirmed negative with consenting for DNA banking and genetic studies. \nWe have a ongoing recruitment of healthy individuals into a study of seroepidemiology of antibodies to SARS-CoV-2 with consenting for DNA banking and genetic studies. \nAll banked DNA samples will be genotyped and whole exome sequenced with analyses as per research questions above.\n","researchCategory":["Disease severity","Immunologic response"],"studyDesignUnformatted":"We have an existing Penn Medicine Biobank of ~60,000 participants consented for genetic studies and EHR data and are actively following up these individuals for those who get infected with SARS-CoV-2.\nWe are prospectively consenting and obtaining DNA from COVID-19 inpatients from Penn Medicine hospitals and contemporaneous inpatient controls.\nWe are prospectively recruiting outpatients with a confirmed diagnosis of COVID-19 and controls who were tested by nasal swab and confirmed negative with consenting for DNA banking and genetic studies. \nWe have a ongoing recruitment of healthy individuals into a study of seroepidemiology of antibodies to SARS-CoV-2 with consenting for DNA banking and genetic studies. \nAll banked DNA samples will be genotyped and whole exome sequenced with analyses as per research questions above.","timeCreated":1585942572000,"hasSubmittedData":true,"id":"rechQEGFG9QeesiSO"},{"shouldShowContactButton":true,"study":"POLCOVID-Genomika","investigator":"Miroslaw Kwasniewski, Marcin Moniuszko","affiliation":"Medical University of Bialystok (leader) and IMAGENE.ME SA (technological partner)","country":"Poland","city":"Bialystok","prospective":true,"prospectiveSampleSize":1450,"wes":true,"assaysPlanned":["Viral sequencing","Transcriptomics","Metabolomics","Immune profiling","Antibody profiling","Proteomics"],"researchQuestion":"The aim of he POLCOVID-Genomika study is to find and understand genetic predispositions affecting the SARS-CoV-2 infection susceptibility, course of disease and the effectiveness of treatment.\n","studyDesign":"The POLCOVID-Genomika project will be implemented by a consortium of Medical University of Bialystok (leader), the Institute of Tuberculosis and Lung Diseases in Warsaw, 9 main hospitals in Poland and IMAGENE.ME biotechnology company. Up to 1450 patients hospitalized for COVID-19 will be enrolled into the study. Inclusion criteria: patients at least 18 years old with confirmed SARS-CoV-2 infection and with different disease course. Exclusion criteria: patient's disagreement, comorbid mental illness, co-existing cancer, post-transplant immunosuppression. WES will be carried out on blood samples. Comprehensive bioinformatic and statistical analyses of sequencing results will be carried out to identify genetic determinants of SARS-CoV-2 infection susceptibility, the disease severity and effectiveness of treatment. Finally, a mobile and web application for prognosis and treatment decision support will be developed and tested retrospectively.\n","researchCategory":["Disease severity","Disease susceptibility"],"studyDesignUnformatted":"The POLCOVID-Genomika project will be implemented by a consortium of Medical University of Bialystok (leader), the Institute of Tuberculosis and Lung Diseases in Warsaw, 9 main hospitals in Poland and IMAGENE.ME biotechnology company. Up to 1450 patients hospitalized for COVID-19 will be enrolled into the study. Inclusion criteria: patients at least 18 years old with confirmed SARS-CoV-2 infection and with different disease course. Exclusion criteria: patient's disagreement, comorbid mental illness, co-existing cancer, post-transplant immunosuppression. WES will be carried out on blood samples. Comprehensive bioinformatic and statistical analyses of sequencing results will be carried out to identify genetic determinants of SARS-CoV-2 infection susceptibility, the disease severity and effectiveness of treatment. Finally, a mobile and web application for prognosis and treatment decision support will be developed and tested retrospectively.","timeCreated":1585956919000,"hasSubmittedData":false,"id":"recwgatErJJMeDkIw"},{"shouldShowContactButton":true,"study":"Qatar Genome Program","investigator":"Hamdi Mbarek","affiliation":"Qatar Genome","country":"Qatar","city":"Doha","retrospective":true,"retrospectiveSampleSize":1000,"prospectiveSampleSize":1000,"genotyping":true,"wgs":true,"researchQuestion":"### identify genetic determinants of COVID-19 susceptibility \n\n","studyDesign":"GWAS and WGS \n","researchCategory":["Disease severity","Disease susceptibility"],"studyDesignUnformatted":"GWAS and WGS ","timeCreated":1585995505000,"hasSubmittedData":true,"id":"recfsjhIsnQv7FjVt"},{"shouldShowContactButton":true,"study":"EXCEED","investigator":"Martin Tobin","affiliation":"University of Leicester","country":"United Kingdom","city":"Leicester","studyLink":"http://www.leicsrespiratorybru.nihr.ac.uk/our-research/our-research-studies/exceed/","retrospective":true,"retrospectiveSampleSize":500,"genotyping":true,"assaysPlanned":["Antibody profiling"],"researchQuestion":"contribution to genome-wide association studies of COVID-19 susceptibility and severity\n","studyDesign":"Longitudinal population study of 10,200 participants with extensive linkage to UK NHS Healthcare records (DNA in all & ~5000 with GWAS data to date, imputed to HRC). Further   recruitment from BAME communities to start April 2020.\nConsent for recruit by genoytpe\n Cohort profile: <https://doi.org/10.1093/ije/dyz073>\n","researchCategory":["Disease severity","Disease susceptibility"],"studyDesignUnformatted":"Longitudinal population study of 10,200 participants with extensive linkage to UK NHS Healthcare records (DNA in all & ~5000 with GWAS data to date, imputed to HRC). Further   recruitment from BAME communities to start April 2020.\nConsent for recruit by genoytpe\n Cohort profile: https://doi.org/10.1093/ije/dyz073","timeCreated":1586010913000,"hasSubmittedData":true,"id":"recwI4pMfG4cBOwts"},{"shouldShowContactButton":false,"study":"UK Biobank","investigator":"Approved researchers","affiliation":"Approved researchers","country":"United Kingdom","city":"Stockport","studyLink":"https://www.ukbiobank.ac.uk/","retrospective":true,"retrospectiveSampleSize":500000,"genotyping":true,"wes":true,"wgs":true,"otherAssays":"GWAS data already available (HRC imputed), TOPMED imputed data not yet available, sequencing data in subset\n","researchQuestion":"Broad range of analyse possible using longitudinal follow up of existing participants using data described (see \"study design\") also check <http://www.bugbank.uk/>\n","studyDesign":"**UK Biobank** - 500,000 participants aged 40-69 at baseline (2006-2010), ~5% non-European ancestry, well described elsewhere e.g. PMID: 26423011, PMID: 30305743.\n**Linked data:**\nCovid-19 test results (Public Health England) \nPrimary care data (Read Codes) - anticipate ~monthly updates\nHospital Episode Statistics (HES) -anticipate ~monthly updates \nICU data (ICNARC)\nMortality data (including cause) \nOther data:\nPlanned serology in subset (~20K including participants & offspring & some grandchildren) \nPossible linkage to symptom tracker(s)\nOver time, new questionnaires informed by a UK Longitudinal Population Studies working group\n \n","researchCategory":["Disease severity","Disease susceptibility","Immunologic response"],"studyDesignUnformatted":"UK Biobank - 500,000 participants aged 40-69 at baseline (2006-2010), ~5% non-European ancestry, well described elsewhere e.g. PMID: 26423011, PMID: 30305743.\nLinked data:\nCovid-19 test results (Public Health England) \nPrimary care data (Read Codes) - anticipate ~monthly updates\nHospital Episode Statistics (HES) -anticipate ~monthly updates \nICU data (ICNARC)\nMortality data (including cause) \nOther data:\nPlanned serology in subset (~20K including participants & offspring & some grandchildren) \nPossible linkage to symptom tracker(s)\nOver time, new questionnaires informed by a UK Longitudinal Population Studies working group\n ","timeCreated":1586012381000,"hasSubmittedData":true,"id":"recTk27XcFrIl3dNs"},{"shouldShowContactButton":true,"study":"Corea (Genetics of COVID-related Manifestation)","investigator":"Han-Na Kim, Eun-Jeong Joo, Soo-kyung Park, Hyung-Lae Kim, Yoosoo Chang, Seungho Ryu, Hyo-Jung Lee, Kyoung-Un Park, Cheol-Min Shin, Si-Hyuck Kang, Hye-Seung Lee, Hyejin Lee, Keun-Yong Eom, Woo-Jin Jeong, Chang Kyung Kang, Hong Bin Kim, Eu Suk Kim, Kyoung-Ho Song, Jongtak Jung, Sinyoung Ham, Jeong Su Park, Wan Beom Park","affiliation":"Kangbuk Samsung Hospital (KBSMC), Ewha Womans University, Seoul National University Bundang Hospital (SNUBH), and Seoul National University Hospital (SNUH)","country":"South Korea","city":"Seoul","retrospective":true,"retrospectiveSampleSize":6000,"genotyping":true,"assaysPlanned":["Antibody profiling"],"otherAssays":"Metagenomics\n","researchQuestion":"Basically, deciphering the host genotype – clinical phenotype relationship the COVID infected.\n1) What host genetics factors could affect the severity of the infection.\n2) What host genetics factors, including immunogenetics make the infected patients with the old aged and the underlying diseases very poor outcome. \n3) What the significance of clinical manifestation other than a respiratory symptom; are there other specific host genetic factors?\nThis effort can contribute the refining the therapeutic modalities, prevention strategies of the disease.\n\n","studyDesign":"1\\. Genetic analyses of various disease features and complications:\n\\- Clinical Data and Biobank\n1) EMR, laboratory testing data, and questionnaires of joining hospitals of South Korea from active surveillance.\n2) Major issues of clinical manifestation: disease course, disease severity, complications.\n3) Recruit new samples into biobank\n2\\. Sequencing and genotyping\n1) Viral genome; RT-PCR, sequencing\n2) Host genome; genotyping and sequencing\n3) Metagenome (gut & oral); v4-16S, shotgun-WGS\n\n","researchCategory":["Disease severity","Immunologic response"],"studyDesignUnformatted":"1. Genetic analyses of various disease features and complications:\n- Clinical Data and Biobank\n1) EMR, laboratory testing data, and questionnaires of joining hospitals of South Korea from active surveillance.\n2) Major issues of clinical manifestation: disease course, disease severity, complications.\n3) Recruit new samples into biobank\n2. Sequencing and genotyping\n1) Viral genome; RT-PCR, sequencing\n2) Host genome; genotyping and sequencing\n3) Metagenome (gut & oral); v4-16S, shotgun-WGS\n","timeCreated":1586079091000,"hasSubmittedData":true,"id":"recXCAR1b2e5qzVC6"},{"shouldShowContactButton":true,"study":"Determining the Molecular Pathways and Genetic Predisposition of the Acute Inflammatory Process Caused by SARS-CoV-2","investigator":"Marta E. Alarcón-Riquelme","affiliation":"GENYO-Center for Genomics and Oncological Research","country":"Spain","city":"Granada","prospective":true,"prospectiveSampleSize":1300,"genotyping":true,"otherAssays":"Methylation with EPIC arrays\n","researchQuestion":"Genetic predisposition to develop severe inflammation in the Spanish and Italian populations\n","studyDesign":"three centers are recruiting cases as they come to the hospitals for screening for SARS-CoV2 by PCR. After informed consent, a blood sample is obtained and frozen. Patients are followed as to the development of their disease. A set of negative individuals will be kept (200) and the positive ones will be analyzed as to the development of hyperinflammation or complete resolution of the infection. Methylation will be used to cluster patients according to inflammatory markers and to identify meQTLS. For some patients (200) immune profiling will be available as well as antibody profiling.\n","researchCategory":["Immunologic response"],"studyDesignUnformatted":"three centers are recruiting cases as they come to the hospitals for screening for SARS-CoV2 by PCR. After informed consent, a blood sample is obtained and frozen. Patients are followed as to the development of their disease. A set of negative individuals will be kept (200) and the positive ones will be analyzed as to the development of hyperinflammation or complete resolution of the infection. Methylation will be used to cluster patients according to inflammatory markers and to identify meQTLS. For some patients (200) immune profiling will be available as well as antibody profiling.","timeCreated":1586256252000,"hasSubmittedData":true,"id":"recXPK99rmBAseQRw"},{"shouldShowContactButton":true,"study":"Canadian Pharmacogenomics Network for Drug Safety (CPNDS)","investigator":"Bruce Carleton, Colin Ross","affiliation":"UBC","country":"Canada","city":"Vancouver","prospective":true,"prospectiveSampleSize":1500,"genotyping":true,"otherAssays":"Genotyping\n","researchQuestion":"A study to explore the host prognostic and pharmacogenomic factors contributing to the wide variability in COVID-19 outcomes. \n","studyDesign":"An analysis of host genetic factors of COVID-19 patients that contribute to disease outcome. \n","researchCategory":["Disease severity","Therapeutics"],"studyDesignUnformatted":"An analysis of host genetic factors of COVID-19 patients that contribute to disease outcome. ","timeCreated":1586282694000,"hasSubmittedData":false,"id":"recNMhI9FxgdCMYS2"},{"shouldShowContactButton":true,"study":"Adolescent Brain and Cognitive development study","investigator":"Alexander S. Hatoum, Emma C. Johnson, Arpana Agrawal, Ryan Bogdan.","affiliation":"Washington University St. Louis, and the ABCD consortium","country":"United States","city":"St. Louis","studyLink":"https://www.nimh.nih.gov/research/research-funded-by-nimh/research-initiatives/adolescent-brain-cognitive-development-abcd-study.shtml","retrospective":true,"retrospectiveSampleSize":200,"genotyping":true,"researchQuestion":"Are genetic variants associated with COVID diagnosis in adolescence (11-13, mean age 12, standard deviation around 6 months)?  How do these results compare to adults?\n","studyDesign":"We have approximately 4539 people of European descent and ~1190 African American individuals with usable GWAS array data.  The goal will be to conduct GWAS of (1) COVID diagnosis and (2) COVID severity in early adolescence.    The consortium is collecting reports from families of diagnosis of children, method of diagnosis, and severity now.  A GWAS pipeline was built using GCTA-loco to account for sample relatedness.  Data collection is about to begin. \n","researchCategory":["Pediatrics"],"studyDesignUnformatted":"We have approximately 4539 people of European descent and ~1190 African American individuals with usable GWAS array data.  The goal will be to conduct GWAS of (1) COVID diagnosis and (2) COVID severity in early adolescence.    The consortium is collecting reports from families of diagnosis of children, method of diagnosis, and severity now.  A GWAS pipeline was built using GCTA-loco to account for sample relatedness.  Data collection is about to begin. ","timeCreated":1586370637000,"hasSubmittedData":false,"id":"recps7WAyc4ek72oA"},{"shouldShowContactButton":true,"study":"Bonn Study of COVID19 genetics","investigator":"Markus Nöthen, Kerstin Ludwig","affiliation":"University Hospital Bonn","country":"Germany","city":"Bonn","retrospective":true,"prospective":true,"genotyping":true,"wgs":true,"researchQuestion":"To identify genetic determinants of (i) disease course and severity, and (ii) individual response towards viral exposure.\n","studyDesign":"We will apply diverse study designs, including extreme phenotypes and population-based samples.\n","studyDesignUnformatted":"We will apply diverse study designs, including extreme phenotypes and population-based samples.","timeCreated":1586426919000,"hasSubmittedData":true,"id":"recRCYA8GXUeQ8ntR"},{"shouldShowContactButton":true,"study":"Coronagenes","investigator":"Albert Tenesa, Jim Wilson","affiliation":"University of Edinburgh","country":"Scotland","city":"Edinburgh","studyLink":"ed.ac.uk/coronagenes","prospective":true,"prospectiveSampleSize":100000,"genotyping":true,"assaysPlanned":["Antibody profiling"],"researchQuestion":"Understand genetic susceptibility to coronavirus, and genetic effects on severity and duration of symptoms, particularly for less severe cases.\n Investigate the psychological effects of long-term self-isolation.\n","studyDesign":"Coronagenes will recruit volunteers from all countries and ethnicities, consent them and administer a baseline questionnaire on health and daily symptom questionnaires through our online system. Participants will consent to genome-wide genetic analysis and antibody testing after lockdowns are relaxed, and to recontact for research purposes. UK participants will have linkage to electronic health records. The subset of volunteers with direct-to-consumer genotypes available will be invited to upload these to allow genetic studies in real time.\n","studyDesignUnformatted":"Coronagenes will recruit volunteers from all countries and ethnicities, consent them and administer a baseline questionnaire on health and daily symptom questionnaires through our online system. Participants will consent to genome-wide genetic analysis and antibody testing after lockdowns are relaxed, and to recontact for research purposes. UK participants will have linkage to electronic health records. The subset of volunteers with direct-to-consumer genotypes available will be invited to upload these to allow genetic studies in real time.","timeCreated":1586428079000,"hasSubmittedData":true,"id":"rec4xEcgOCdajba7U"},{"shouldShowContactButton":true,"study":"ACCOuNT","investigator":"Minoli Perera, David Meltzer","affiliation":"Northwestern University, University of Chicago","country":"United States","city":"Chicago","retrospective":true,"retrospectiveSampleSize":1300,"genotyping":true,"researchQuestion":"Does unique genetic variation in African Americans associated to risk of COVID-19 diagnosis or severity.  \n","studyDesign":"I currently Dr. Perera and Dr. Meltzer co-leader of a multi-site consortium focused on African American pharmacogenomics in cardiovascular disease. Through this consortium we have recruited approximately 1300 African Americans, in which we have collected extensive medical histories, comorbidities, clinical lab measures and biological samples. Given the emerging disparity in COVID-19 deaths and severity in African Americans, these cohorts are ideally suited to investigate if there is a genomic contributor to COVID-19 infection and severity.  We will retrospectively survey our participants for relevant COVID-19 phenotypes (positive COVID-19 test results, hospitalization from COVID-19, intubation, and death) through each institutions’ electronic health record.  Currently we are recruiting in 3 sites in Chicago and 2 sites in Washington DC.  We will conduct additional genotyping (for those that have not been genotyped to date) or use the already obtained genome-wide genotypes to assess if genetic variants in African Americans contribute to risk.  We will analyze these data in several ways: First by genome-wide association analysis, which will unbiasedly survey the entire genome for association to each of the COVID-19 phenotypes, using the case/control designs that the consortium has described.  If we are underpowered for this type of analysis, we will focus on specific genes that have known disparities between populations and with a suggestive link to viral infection.  Lastly, we will conduct gene-based association analysis.\n","studyDesignUnformatted":"I currently Dr. Perera and Dr. Meltzer co-leader of a multi-site consortium focused on African American pharmacogenomics in cardiovascular disease. Through this consortium we have recruited approximately 1300 African Americans, in which we have collected extensive medical histories, comorbidities, clinical lab measures and biological samples. Given the emerging disparity in COVID-19 deaths and severity in African Americans, these cohorts are ideally suited to investigate if there is a genomic contributor to COVID-19 infection and severity.  We will retrospectively survey our participants for relevant COVID-19 phenotypes (positive COVID-19 test results, hospitalization from COVID-19, intubation, and death) through each institutions’ electronic health record.  Currently we are recruiting in 3 sites in Chicago and 2 sites in Washington DC.  We will conduct additional genotyping (for those that have not been genotyped to date) or use the already obtained genome-wide genotypes to assess if genetic variants in African Americans contribute to risk.  We will analyze these data in several ways: First by genome-wide association analysis, which will unbiasedly survey the entire genome for association to each of the COVID-19 phenotypes, using the case/control designs that the consortium has described.  If we are underpowered for this type of analysis, we will focus on specific genes that have known disparities between populations and with a suggestive link to viral infection.  Lastly, we will conduct gene-based association analysis.","timeCreated":1586539506000,"hasSubmittedData":true,"id":"recfkhUo3jvKKbT8v"},{"shouldShowContactButton":true,"study":"COVID19-Host(a)ge","investigator":"Andre Franke, Tom Hemming Karlsen","affiliation":"Kiel University and University Hospitals of Oslo and Schleswig-HolsteinCO","country":"Germany","city":"Kiel","retrospective":true,"retrospectiveSampleSize":4000,"genotyping":true,"assaysPlanned":["Antibody profiling"],"otherAssays":"test antibody assay on subset; if meaningful and feasible from EDTA blood then run on whole cohort\n","researchQuestion":"Severe vs. mild disease\n","studyDesign":"Case-only analysis; Samples are mainly from hotspots in Italy and Spain.\n","studyDesignUnformatted":"Case-only analysis; Samples are mainly from hotspots in Italy and Spain.","timeCreated":1586859494000,"hasSubmittedData":true,"id":"recDrk69I49Euz9r2"},{"shouldShowContactButton":true,"study":"UK Blood Donors Cohort","investigator":"Adam Butterworth, Emanuele Di Angelantonio, John Danesh","affiliation":"University of Cambridge","country":"United Kingdom","city":"Cambridge","studyLink":"https://www.intervalstudy.org.uk/","retrospective":true,"retrospectiveSampleSize":800,"genotyping":true,"researchQuestion":"A multipurpose recallable bioresource to understand the genetic determinants of molecular traits and clinical outcomes. \n","studyDesign":"~80,000 blood donors aged 18-80 recruited at sites across England from 2012 onwards into a 'multi-omics' bioresource. All participants have genetic data and are linked to health records. Subsets have molecular assays, including transcriptomics, proteomics, blood cell traits, metabolomics, lipidomics etc.\n","studyDesignUnformatted":"~80,000 blood donors aged 18-80 recruited at sites across England from 2012 onwards into a 'multi-omics' bioresource. All participants have genetic data and are linked to health records. Subsets have molecular assays, including transcriptomics, proteomics, blood cell traits, metabolomics, lipidomics etc.","timeCreated":1586965357000,"hasSubmittedData":true,"id":"recDKbt8iTidvjRSi"},{"shouldShowContactButton":true,"study":"Saudi Human Genome Program- COVID19 : Host Genomic markers predicting the severity and suitability to COVID-19 in highly consanguineous population","investigator":"Saudi Human Genome Program ","affiliation":"King Abdulaziz City for Science and Technology ( KACST)","country":"Saudi Arabia","city":"Riyadh","studyLink":"https://www.saudigenomeprogram.org/en/","retrospective":true,"prospective":true,"retrospectiveSampleSize":10000,"prospectiveSampleSize":3000,"genotyping":true,"wes":true,"wgs":true,"researchQuestion":"Our primary research question is to investigate genetic links that could predispose individuals to severe COVID-19 symptoms or disease susceptibility \n","studyDesign":"The Saudi Human Genome Program (SHGP) is one of the National Transformation Programs of Vision 2030 for Saudi Arabia. It aims at sequencing more than 100,000 Human genomic samples to identifying the genetic basis of rare and common diseases in the Saudi population. COVID-19 pandemic is a global crisis creating severe disruptions across the economy and health system. Insights into how to better understand and treat COVID-19 are desperately needed. SHGP aims to generate, share, and analyze data to learn the genetic determinants of COVID-19 susceptibility, severity, and outcomes in our highly consanguineous population**. **Our SHGP** **database containing thousands of genotyped and sequenced individuals, combined with our ability to quickly reach our participants, make us able to address questions related to the genetics of COVID-19, outcomes discoveries could help to identify individuals at unusually high or low risk. Using those data, our researchers will conduct a genome-wide association study (GWAS) to determine if any genetic variants are associated with severity of COVID-19 symptoms or disease susceptibility.  \n","studyDesignUnformatted":"The Saudi Human Genome Program (SHGP) is one of the National Transformation Programs of Vision 2030 for Saudi Arabia. It aims at sequencing more than 100,000 Human genomic samples to identifying the genetic basis of rare and common diseases in the Saudi population. COVID-19 pandemic is a global crisis creating severe disruptions across the economy and health system. Insights into how to better understand and treat COVID-19 are desperately needed. SHGP aims to generate, share, and analyze data to learn the genetic determinants of COVID-19 susceptibility, severity, and outcomes in our highly consanguineous population. Our SHGP database containing thousands of genotyped and sequenced individuals, combined with our ability to quickly reach our participants, make us able to address questions related to the genetics of COVID-19, outcomes discoveries could help to identify individuals at unusually high or low risk. Using those data, our researchers will conduct a genome-wide association study (GWAS) to determine if any genetic variants are associated with severity of COVID-19 symptoms or disease susceptibility.  ","timeCreated":1586981915000,"hasSubmittedData":true,"id":"recwVYBNm41lje7le"},{"shouldShowContactButton":true,"study":"Genetic influences on severity of COVID-19 illness in Korea","investigator":"Jong Eun Lee, Jay Lee, Sungmin Kym, Yeon-Sook Kim,  Ki Tae Kwon, Shin-Woo Kim, Jin Yong Kim, Hyun Ah Kim, Sun Hee Lee, Shinwon Lee, Kang-Won Choe, Jae-Phil Choi, Sarah Pendergrass, Diana Chang, Brian Yaspan, Christian Hammer, Carrie Rosenberger, Julie Hunkapiller, Mark McCarthy","affiliation":"Jong Eun Lee, DNALink, Seoul, Korea; Jay Lee, DNALink, Seoul, Korea; Sungmin Kym, Chungnam National University Hospital, Sejong, Korea; Yeon-Sook Kim,  Chungnam National University Hospital, Daejeon, Korea; Ki Tae Kwon, Kyungpook National University Hospital, Daegu, Korea; Shin-Woo Kim, Kyungpook National University Hospital, Daegu, Korea; Jin Yong Kim, Incheon Medical Center, Incheon, Korea; Hyun Ah Kim, Keimyung University Dongsan Hospital, Daegu, Korea; Sun Hee Lee, Pusan National University Hospital, Busan, Korea; Shinwon Lee,  Pusan National University Hospital, Busan, Korea; Kang-Won Choe, Myongji Hospital, Goyang, Gyeonggi, Korea; Jae-Phil Choi, Seoul Medical Center, Seoul, Korea; Sarah Pendergrass, Diana Chang, Brian Yaspan, CHristian HAmmer, Carrie Rosenberger, Julie Hunkapiller, Mark McCarthy, Genentech, South San Francisco, USA","country":"South Korea","city":"Seoul, Busan, Daegu, Incheon, Sejong, Daejeon, Gyeonggi (Korea); South San Francisco (USA)","prospective":true,"prospectiveSampleSize":1000,"genotyping":true,"assaysPlanned":["Antibody profiling"],"researchQuestion":"GWAS for respiratory outcomes of COVID-19 infection\n","studyDesign":"\\>1000 cases (hospitalization for COVID19 related respiratory disease in early 2020) ascertained during hospitalization or subsequently (whilst convalescing). \n\\>70K historical population controls from Korea (already ascertained & genotyped)\nAll typed on the same Affymetrix array (enhanced for Korean relevant content), and imputed using Korean WGS data. \nClinical data collection based on COVID collaboration template. \n","studyDesignUnformatted":">1000 cases (hospitalization for COVID19 related respiratory disease in early 2020) ascertained during hospitalization or subsequently (whilst convalescing). \n>70K historical population controls from Korea (already ascertained & genotyped)\nAll typed on the same Affymetrix array (enhanced for Korean relevant content), and imputed using Korean WGS data. \nClinical data collection based on COVID collaboration template. ","timeCreated":1587101651000,"mapLocation":"Korea, Incheon","hasSubmittedData":true,"id":"rec2gNEtx6Q0czdQL"},{"shouldShowContactButton":true,"study":"WHOLE GENOME SEQUENCING ANALYSIS OF COVID-19 POSITIVE PATIENTS","investigator":"Sandra Smieszek, Ph.D., Christos Polymeropoulos, MD","affiliation":"Vanda Pharmaceuticals Inc.","country":"United States","city":"DC","prospective":true,"prospectiveSampleSize":5000,"wgs":true,"assaysPlanned":["Viral sequencing","Transcriptomics","Proteomics","Immune profiling"],"researchQuestion":"host-virus interaction\noutcome associations\nseverity associations\n","studyDesign":"·      The objective of this study is to analyze whole genome sequencing samples from SARS-CoV-2 positive patients (SARS-CoV-2 assessed by RT-PCR from sputum or nasopharyngeal samples) along with viral genome and viral load.\n·      The inclusion criteria include confirmed SARS-CoV-2 infection and willingness to comply with study procedures.\n·      The study design includes a screening and follow up phase. Severity will be assessed during both screening and follow up.\n·      During screening patient will be assessed for severity and samples will be collected from consented individuals with a confirmed SARS-CoV-2 infection. \n·      Samples will include a sputum or nasopharyngeal sample, a blood samples, and a buccal swab. \n·      Data will be ultimately shared with global research community\n","studyDesignUnformatted":"·      The objective of this study is to analyze whole genome sequencing samples from SARS-CoV-2 positive patients (SARS-CoV-2 assessed by RT-PCR from sputum or nasopharyngeal samples) along with viral genome and viral load.\n·      The inclusion criteria include confirmed SARS-CoV-2 infection and willingness to comply with study procedures.\n·      The study design includes a screening and follow up phase. Severity will be assessed during both screening and follow up.\n·      During screening patient will be assessed for severity and samples will be collected from consented individuals with a confirmed SARS-CoV-2 infection. \n·      Samples will include a sputum or nasopharyngeal sample, a blood samples, and a buccal swab. \n·      Data will be ultimately shared with global research community","timeCreated":1587402464000,"hasSubmittedData":false,"id":"recpCqa5dUvLlzvUp"},{"shouldShowContactButton":true,"study":"Host genetic factors in COVID-19 patients in relation to disease susceptibility, disease severity and pharmacogenomics","investigator":"Pajaree Chariyavilaskul, Monpat Chamnanphol, Noppadol Wacharachaisurapol, Voraphoj Nilatanakul, Opass Putcharoen, Watsmon Jantarabenhakul, Nattiya Hirankarn, Vorasuk Shotelersuk","affiliation":"Faculty of Medicine, Chulalongkorn University","country":"Thailand","city":"Bangkok","retrospective":true,"prospective":true,"retrospectiveSampleSize":300,"prospectiveSampleSize":200,"genotyping":true,"assaysPlanned":["Immune profiling"],"otherAssays":"HLA class I and II, ACE1&2 and pharmacogenomics of drug metabolizing enzyme and drug transporters\n","researchQuestion":"\tOur team foresee the importance of host genetic factors including human leukocyte antigen (HLA), angiotensin converting enzyme (ACE) 1 and 2 and the diversity of drug metabolizing enzymes and drug transporters that might affect pharmacokinetics and pharmacodynamics of drugs used in COVID-19 patients. These host genetic factors would help identify individuals who are at risk for disease (disease susceptibility, or disease severity). Also, the data will help tailoring the treatment regimen for the patients and thus improve the overall treatment outcome.\n","studyDesign":"We will collect blood samples from COVID-19 patients who were treated at King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Thailand and Bamrasnaradura Infectious Disease Institute, Ministry of Health, Thailand and study their genetic variations of HLA, ACE1&2 and pharmacogenomics of drug metabolizing enzyme and drug transporters that are related to drug used in COVID-19 (chloroquine/ hydroxychloroquine, darunavir + ritonavir, lopinavir/ritonavir and favipiravir). All genetic data will be related to the disease susceptibility, disease severity and drug response in those patients. These will be an exclusive set of data for our COVID-19 Thai patients. \n","studyDesignUnformatted":"We will collect blood samples from COVID-19 patients who were treated at King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Thailand and Bamrasnaradura Infectious Disease Institute, Ministry of Health, Thailand and study their genetic variations of HLA, ACE1&2 and pharmacogenomics of drug metabolizing enzyme and drug transporters that are related to drug used in COVID-19 (chloroquine/ hydroxychloroquine, darunavir + ritonavir, lopinavir/ritonavir and favipiravir). All genetic data will be related to the disease susceptibility, disease severity and drug response in those patients. These will be an exclusive set of data for our COVID-19 Thai patients. ","timeCreated":1587536042000,"hasSubmittedData":true,"id":"recWY1yHRS9QNU0oy"},{"shouldShowContactButton":true,"study":"24Genetics & IdiPaz Genomic Variants associated to Covid19 infection outcome","investigator":"Eduardo López-Collazo, Alejandro Martín-Quirós, Juan Carlos Figueira Iglesias, Jose Avendaño-Ortiz, Roberto Lozano, Luis A Aguirre, Charbel Maroun Eid, Jaime Valentín Quiroga, Karla Montalbán-Hernández, Rosario Torres Santos Olmo, Angélica Rivera Núñez, Juan Ignacio Esteban Miñano, Manuel de la Mata Pazos, Lasse Folkersen, Luciano Cerrato","affiliation":"24Genetics -  IdiPaz","country":"Spain","city":"Madrid","studyLink":"https://24genetics.com/en/covid19-dna-research","retrospective":true,"prospective":true,"retrospectiveSampleSize":500,"prospectiveSampleSize":500,"genotyping":true,"researchQuestion":"Certain SNPs may have a correlation with the clinical evolution of COVID19 patients. Their identification would indicate which genes could be involved in the development of a state of severity in these patients.\n","studyDesign":"We will ask for participation to thousands of 24Genetics clients from more than 95 countries; this will give us a very fast action. We will also genotype up to 500 additional segmented Covid19 patients from Hospitals in Spain. Gwas plus some other bioinformatic research will be done to find SNP based correlations with Covid19, but also relationships between our 24Genetics existing trait algorithms and the virus, including ethnics (ancestry), biometrics, biomarkers and disease predisposition.\n","studyDesignUnformatted":"We will ask for participation to thousands of 24Genetics clients from more than 95 countries; this will give us a very fast action. We will also genotype up to 500 additional segmented Covid19 patients from Hospitals in Spain. Gwas plus some other bioinformatic research will be done to find SNP based correlations with Covid19, but also relationships between our 24Genetics existing trait algorithms and the virus, including ethnics (ancestry), biometrics, biomarkers and disease predisposition.","timeCreated":1587574063000,"hasSubmittedData":true,"id":"recXqcIOBmPRmfXLc"},{"shouldShowContactButton":true,"study":"Extreme-genotype-comparison and extreme-clinical-phenotype-comparison in CoV-2 patients: direct candidate genes-pathways and GWAS.","investigator":"Gemmati Donato","affiliation":"University of Ferrara","country":"Italy","city":"Ferrara","retrospective":true,"genotyping":true,"wes":true,"wgs":true,"assaysPlanned":["Immune profiling"],"otherAssays":"Citokine's multiplex assays, molecular pathway of endothelial dysfunction, Pharmacogenetics/Pharmacogenomics.\n","researchQuestion":"Individual genetic susceptibility to CoV2 infection and progression to COVID19, Sex-disparities in prognosis: GWAS, candidate genes, Pharmacogenetics/Pharmacogenomics, Epigenetics investigations\n","studyDesign":"To recruit DNA from biological samples of COV-2 infected patients (male/female sex balanced), regardless age, comorbidities and concomitant treatments: genomic analyses (GWAS and candidate gene analyses).\n","studyDesignUnformatted":"To recruit DNA from biological samples of COV-2 infected patients (male/female sex balanced), regardless age, comorbidities and concomitant treatments: genomic analyses (GWAS and candidate gene analyses).","timeCreated":1587739391000,"hasSubmittedData":false,"id":"rec0CufBJdOxdaest"},{"shouldShowContactButton":true,"study":"Helix Exome+ COVID-19 Phenotypes","investigator":"Liz Cirulli; Nicole Washington; James Lu; Alexandre Bolze; Kelly Barrett","affiliation":"Helix","country":"United States","city":"San Mateo","retrospective":true,"wes":true,"researchQuestion":"We are interested in identifying genetic variant that influence human response to SARS-CoV2.\n","studyDesign":"We will analyze Exome+ sequence data from individuals who have responded to surveys asking about COVID-19 phenotypes and behaviors.\n","studyDesignUnformatted":"We will analyze Exome+ sequence data from individuals who have responded to surveys asking about COVID-19 phenotypes and behaviors.","timeCreated":1588116940000,"hasSubmittedData":true,"id":"recIoTiw4uN2Thmlx"},{"shouldShowContactButton":true,"study":"MyCode Health Initiative","investigator":"Anne E Justice, Tooraj Mirshahi, Geetha Chittoor, Jon Luo, Navya Josyula","affiliation":"Geisinger","country":"United States","city":"Danville, PA","retrospective":true,"genotyping":true,"wes":true,"researchQuestion":"The overall goal of the project is to identify risk factors (genetic and clinical) for poor health outcomes resulting from SARS-CoV-2 infection in the Geisinger patient population. \n","studyDesign":"We are an EHR-linked BioBank, so cases are identified as they are diagnosed. We will track outcomes of those that are tested positive (i.e. admitted, ICU, ventilator, sent home, deceased). We will use prior health record data to inform our analyses on non-genetic risk factors.\n","studyDesignUnformatted":"We are an EHR-linked BioBank, so cases are identified as they are diagnosed. We will track outcomes of those that are tested positive (i.e. admitted, ICU, ventilator, sent home, deceased). We will use prior health record data to inform our analyses on non-genetic risk factors.","timeCreated":1588171837000,"hasSubmittedData":true,"id":"rec4UfVJIT3sfqYEm"},{"shouldShowContactButton":true,"study":"Is the genetic profile of population a biomarker for therapeutic response in COVID-19 patients or independent indicator of the evolution of SARS-CoV-2 infection?","investigator":"Ruth Zarate, María-Jose Fernández, Gladys Estigarribia Sanabria, Zulema Silguero, Lorena Ocampos, Pahola Bogado Chamorro, Mariel Denisse Romero, Isabel Acosta Colmán, Leticia Ramírez Pastore, Gabriela Ávila, Guillermo Sequera","affiliation":"Centro para el Desarrollo de la Investigación Científica (CEDIC), Universidad Nacional de Caaguazu-Instituto Regional de Investigación en Salud, Facultad de Ciencias Médicas (FCM), Universidad Nacional de Asunción (UNA), and Ministerio de Salud Pública y Bienestar Social (MSPBS)","country":"Paraguay","city":"Asunción","retrospective":true,"prospective":true,"retrospectiveSampleSize":480,"prospectiveSampleSize":800,"genotyping":true,"wgs":true,"researchQuestion":"To identify the genetic profiles on mild and moderate symptoms of SARS-CoV-2 infection in patients >18 years.\n","studyDesign":"Retrospective cases of SARS-CoV- 2 positives with or without risk factors and mild or moderate symtoms. The criteria for inclusion will be adults’ patients of both sexes >18 years old (200 samples).\nMonitoring mutations of concern of SARS-Cov-2 corresponding to the second wave in Paraguay (180 samples). \n","studyDesignUnformatted":"Retrospective cases of SARS-CoV- 2 positives with or without risk factors and mild or moderate symtoms. The criteria for inclusion will be adults’ patients of both sexes >18 years old (200 samples).\nMonitoring mutations of concern of SARS-Cov-2 corresponding to the second wave in Paraguay (180 samples). ","timeCreated":1589363991000,"hasSubmittedData":false,"id":"rec8xEhewzD7YRGj1"},{"shouldShowContactButton":true,"study":"GEN-COVID Project","investigator":"Antonio Salas Ellacuriaga, Federico Martinón Torres","affiliation":"Instituto de Investigación Sanitaria (IDIS), Universidade de Santiago de Compostela, Hospital Clínico Universitario de Santiago de Compostela","country":"Spain","city":"Santiago de Compostela","studyLink":"gencovid.es","retrospective":true,"prospective":true,"retrospectiveSampleSize":400,"prospectiveSampleSize":1000,"genotyping":true,"wes":true,"wgs":true,"assaysPlanned":["Viral sequencing","Transcriptomics","Proteomics","Antibody profiling","Immune profiling"],"otherAssays":"Genome editing (e.g. CRISPR) experiments\n","researchQuestion":"The genetic variability of the host may play a main role in regulating the susceptibility and the severity of the disease, as we and others have been shown in other infectious diseases.\n","studyDesign":"We are using parallel sequencing technologies (NGS), which allow the identification of rare variants that cannot be captured with the genome-wide association studies (GWAS). We are also carrying out complementary GWAS studies. Furthermore, the transcriptomic approach will allow us to identify specific gene expression patterns of the host response to COVID-19 infection, as well as the identification of host expression factors that explain differential phenotypes and clinical courses. We already have collected samples to move in the terrain of epigenomics and proteomics.\n","studyDesignUnformatted":"We are using parallel sequencing technologies (NGS), which allow the identification of rare variants that cannot be captured with the genome-wide association studies (GWAS). We are also carrying out complementary GWAS studies. Furthermore, the transcriptomic approach will allow us to identify specific gene expression patterns of the host response to COVID-19 infection, as well as the identification of host expression factors that explain differential phenotypes and clinical courses. We already have collected samples to move in the terrain of epigenomics and proteomics.","timeCreated":1589373335000,"mapLocation":"Hospital Clínico Universitario de Santiago de Compostela (CHUS), c/ A Choupana s.n., CP: 15706, Santiago de Compostela, Spain","hasSubmittedData":false,"id":"recdw2jLuamNyuF4f"},{"shouldShowContactButton":true,"study":"AncestryDNA COVID-19 Research Study","investigator":"Catherine Ball, Eurie Hong, Kristin Rand","affiliation":"Ancestry","country":"United States","city":"San Francisco","studyLink":"https://www.ancestry.com/cs/covid19-study","retrospective":true,"genotyping":true,"researchQuestion":"To understand the genetic component to how people contract and respond to the SARS-CoV-2 virus. \n","studyDesign":"Analyses will be performed to determine the genetic susceptibility of individuals to the SARS-CoV-2 virus based on an individual’s responses to an online COVID-19 survey .\n","studyDesignUnformatted":"Analyses will be performed to determine the genetic susceptibility of individuals to the SARS-CoV-2 virus based on an individual’s responses to an online COVID-19 survey .","timeCreated":1589919222000,"hasSubmittedData":true,"id":"reciOhoUODhxmN44s"},{"shouldShowContactButton":true,"study":"Generation Scotland","investigator":"Caroline Hayward","affiliation":"MRC Human Genetics Unit, University of Edinburgh","country":"United Kingdom","city":"Edinburgh","studyLink":"https://www.ed.ac.uk/generation-scotland","retrospective":true,"retrospectiveSampleSize":313,"genotyping":true,"researchQuestion":"Analysis of self-reported information from the COVIDlife questionaire to Generation Scotland participants\n","studyDesign":"Generation Scotland (GS) is a family bases cohort with data on genetics, medical, family history and lifestyle information from over 24,000 volunteers from across Scotland. The data for this study comprises of 313 suscpected cases and 3584 controls from the GS study who responded to the COVIDlife questionaire.\n","studyDesignUnformatted":"Generation Scotland (GS) is a family bases cohort with data on genetics, medical, family history and lifestyle information from over 24,000 volunteers from across Scotland. The data for this study comprises of 313 suscpected cases and 3584 controls from the GS study who responded to the COVIDlife questionaire.","timeCreated":1590561025000,"hasSubmittedData":true,"id":"recGmwYC0TmQ2RNed"},{"shouldShowContactButton":true,"study":"SARS-Cov 2 Genomic epidemiology and COVID-19 Host Genetics effect in Morocco","investigator":"Hassan Ghazal, Najib Al Idrissi, Bouchra Ghazi, Salsabil Hamdi, ","affiliation":"University Mohamed VI for Health Sciences, Pasteur Institute Morocco","country":"Morocco","city":"Casablanca","retrospective":true,"prospective":true,"retrospectiveSampleSize":50,"prospectiveSampleSize":200,"wes":true,"wgs":true,"assaysPlanned":["Viral sequencing","Transcriptomics","Immune profiling","Antibody profiling"],"researchQuestion":"An integrated multi-omic approach is required to investigate the complex biological mechanisms involved in SARS-CoV-2 infection, improve the ability to detect and characterize the virus, and assess the impact on the immune system and to propose efficient therapeutic strategies. \n\nSpecific objectives:\n1) Characterization of the genomic epidemiology of SARS-CoV-2 in Morocco\n2) Analysis of genetic susceptibility of COVID-19 patients to virus infection by genome sequencing in correlation with clinical severity in Morocco\n3) Microbiome Characterisation of the Lung and Gut in SARS-Cov 2 patients in Morocco\n4) Antibody profiling of Moroccan Covid 19 patients with grading symptoms\n### \n\n","studyDesign":"The project  includes 1) recruitment of patients at hospitals in Casablanca and a matched group of control from the same population; 2) collection of various samples ( naso-pharyngal cells, peripheral blood and plasma, Lung Sputum, Stools) from cases and controls;\nCohorte : 200 covid 19 patients and 100 covid 19 negative individuals.\nNo comorbodities conditions.\n\nThe experiment design: \n1) Sequencing the Virus RNA Genome isolated from covid-19 patients\n2)  Sequence and analyze Exome and Genome generated from blood samples from individuals showing grading COVID-19 severity phenotypes \n3) Metagenomics 16S and WGS sequencing of sputum and Stool samples from covid 19 patients with severe and Covid 19 negative individuals\n4) Immune profiling over time from Plasma samples collected from patients with various symptoms\n","studyDesignUnformatted":"The project  includes 1) recruitment of patients at hospitals in Casablanca and a matched group of control from the same population; 2) collection of various samples ( naso-pharyngal cells, peripheral blood and plasma, Lung Sputum, Stools) from cases and controls;\nCohorte : 200 covid 19 patients and 100 covid 19 negative individuals.\nNo comorbodities conditions.\n\nThe experiment design: \n1) Sequencing the Virus RNA Genome isolated from covid-19 patients\n2)  Sequence and analyze Exome and Genome generated from blood samples from individuals showing grading COVID-19 severity phenotypes \n3) Metagenomics 16S and WGS sequencing of sputum and Stool samples from covid 19 patients with severe and Covid 19 negative individuals\n4) Immune profiling over time from Plasma samples collected from patients with various symptoms","timeCreated":1590723829000,"hasSubmittedData":false,"id":"recuViLI66aX0Ll0M"},{"shouldShowContactButton":true,"study":"Japan Coronavirus Taskforce","investigator":"Masumi Ai, Koichi Fukunaga, Naoki Hasegawa, Ho Namkoong, Seiya Imoto, Takanori Kanai, Akinori Kimura, Yuko Kitagawa, Ryuji Koike, Atsushi Kumanogoh, Satoru Miyano, Seishi Ogawa, Yukinori Okada, Toshiro Sato, Katsushi Tokunaga","affiliation":"Keio University, Tokyo Medical and Dental University, Osaka University, Institute of Medical Science the University of Tokyo","country":"Japan","city":"Tokyo","studyLink":"https://www.covid19-taskforce.jp/","prospective":true,"prospectiveSampleSize":5000,"genotyping":true,"wgs":true,"assaysPlanned":["Transcriptomics","Metabolomics","Proteomics"],"researchQuestion":"Elucidation of the biological backgrounds and biomarkers responsible for COVID-19 infection outcomes is a scientific question with urgent priority. As noticed, there exists global heterogeneity in morbidity and mortality of COVID-19 infection, which we expect to be disentangled by host genetics efforts of worldwide populations. Japan Coronavirus Taskforce aims to elucidate how genetic backgrounds are associated with clinical outcomes of COVID-19 infection in the Japanese population.\n","studyDesign":"We launched a nation-wide, academia-driven taskforce to proceed COVID-19 human genetics researches in the Japanese population named “Japan Coronavirus Taskforce”. We recruit the subjects affected with COVID-19 from the participating medical institutes and hospitals across Japan. We collect genomic DNA, RNA, and plasma, with detailed clinical information. Our study focuses on genome-wide, transcriptome-wide, and phenome-wide association studies to investigate host genetics and omics factors are responsible for clinical outcomes of COVID-19 infection.\n","studyDesignUnformatted":"We launched a nation-wide, academia-driven taskforce to proceed COVID-19 human genetics researches in the Japanese population named “Japan Coronavirus Taskforce”. We recruit the subjects affected with COVID-19 from the participating medical institutes and hospitals across Japan. We collect genomic DNA, RNA, and plasma, with detailed clinical information. Our study focuses on genome-wide, transcriptome-wide, and phenome-wide association studies to investigate host genetics and omics factors are responsible for clinical outcomes of COVID-19 infection.","timeCreated":1590838221000,"hasSubmittedData":true,"id":"recsBIWxya8fWXZWq"},{"shouldShowContactButton":true,"study":"Latvia COVID-19 research platform","investigator":"Janis Klovins","affiliation":"Latvian Biomedical Research and Study Centre","country":"Latvia","city":"Riga","prospective":true,"prospectiveSampleSize":500,"genotyping":true,"wgs":true,"assaysPlanned":["Viral sequencing","Transcriptomics","Metabolomics","Antibody profiling","Immune profiling"],"otherAssays":"1. Sequencing of viral genomes\n2. GSA genotyping array\n3. Selected cases for WGS\n4. Level of  cytokines\n5. Transcriptome analysis of peripheral blood mononuclear cells\n6.  Microbiome analysis in the oropharyngeal and fecal samples\n7. Blood metabolome analysis\n8. basic biochemical, inflammatory and autoimmune markers \n","researchQuestion":"The goal of the project is to establish an open biobank and data exchange resource to facilitate the research on COVID -19,  create a framework for its integration with health care initiatives and ensure international cooperativity\n","studyDesign":"Objective 1. Create a biobank that involves biological samples, clinical and other information from the majority of COVID-19 patients in Latvia and ensure its immediate  availability for researchers.\n Objective 2. Perform a standardized  analysis of samples from COVID-19 patients for the selected set of biochemical, molecular, immunological and other markers.\nObjective 3: Create an open data platform and provide necessary tools to ensure accessibility of all COVID-19 related clinical and analytical data for research and translation into the health care practice.\n\n\n","studyDesignUnformatted":"Objective 1. Create a biobank that involves biological samples, clinical and other information from the majority of COVID-19 patients in Latvia and ensure its immediate  availability for researchers.\n Objective 2. Perform a standardized  analysis of samples from COVID-19 patients for the selected set of biochemical, molecular, immunological and other markers.\nObjective 3: Create an open data platform and provide necessary tools to ensure accessibility of all COVID-19 related clinical and analytical data for research and translation into the health care practice.\n\n","timeCreated":1591782542000,"hasSubmittedData":true,"id":"rec5elQzAvyvsv5EN"},{"shouldShowContactButton":true,"study":"Host genetic factors contributing to susceptibility to COVID-19 in South Africans","investigator":"Marlo Möller, Desiree Petersen, Reinhard Hiller, Caitlin Uren, Brigitte Glanzmann, Elouise Kroon, Craig Kinnear, Richard Glashoff, Helena Cornelissen, Zivanai Cuthberg Chapanduka, Ibtisam Abdullah, Judith Hornby, ","affiliation":"Stellenbosch University, Centre for Proteomic and Genomics Research, Artisan Biomed, National Health Laboratory Service ","country":"South Africa","city":"Cape Town","prospective":true,"prospectiveSampleSize":5000,"genotyping":true,"wgs":true,"researchQuestion":"To identify the underlying genetic causes of severe COVID-19 disease or resistance in South Africans\n\n","studyDesign":"The Western Cape Province currently has the highest number of reported SARS-CoV-2 infections in South Africa. **We have already obtained a commitment from Artisan Biomed to bank 10 000 buccal swab samples for DNA extraction** for use in future GWAS. We initially intend to whole genome sequence 50 young COVID-19 cases with scores of 5-8 (more susceptible) and 50 older individuals with scores from 0-2 (more resistant) to investigate the genetic cause of these extreme phenotypes of disease\n","studyDesignUnformatted":"The Western Cape Province currently has the highest number of reported SARS-CoV-2 infections in South Africa. We have already obtained a commitment from Artisan Biomed to bank 10 000 buccal swab samples for DNA extraction for use in future GWAS. We initially intend to whole genome sequence 50 young COVID-19 cases with scores of 5-8 (more susceptible) and 50 older individuals with scores from 0-2 (more resistant) to investigate the genetic cause of these extreme phenotypes of disease","timeCreated":1592818840000,"hasSubmittedData":false,"id":"recGgpgQtpqXNcuAJ"},{"shouldShowContactButton":false,"study":"Population controls","country":"Belgium, Italy, Sweden","timeCreated":1593101665000,"hasSubmittedData":false,"id":"recsn6GM2pNEv3f5p"},{"shouldShowContactButton":true,"study":"deCODE genetics","investigator":"Patrick Sulem, Gardar Sveinbjornsson, Kari Stefansson","affiliation":"deCODE genetics","country":"Iceland","city":"Reykjavik","retrospective":true,"genotyping":true,"wgs":true,"researchQuestion":"GWAs of SARS COV2 infection and COVID19 progression in Iceland\n\n\n\n","studyDesign":"GWAs of SARS COV2 infection and COVID19 progression in Iceland\n\nWe have access to genotypes of 1400 SARS COV2 positive case and over 160K controls.\n\n","studyDesignUnformatted":"GWAs of SARS COV2 infection and COVID19 progression in Iceland\n\nWe have access to genotypes of 1400 SARS COV2 positive case and over 160K controls.\n","timeCreated":1593178635000,"hasSubmittedData":true,"id":"recgoUzsIfFpOCjFV"},{"shouldShowContactButton":true,"study":"SARS-CoV-2 and host genome sequencing","investigator":"Fouzia Sadiq, Mohammad Iqbal Khan","affiliation":"University, Hospital","country":"Pakistan","city":"Islamabad","prospective":true,"prospectiveSampleSize":500,"researchQuestion":"What SARS-CoV-2 variants are circulating among the patients from twin city of Islamanbad and Rawalpindi? Is it the virulence of the SARS-CoV-2 or host genetics that is responsible for less number of deaths in Pakistan. \n","studyDesign":"Cross-sectional, Prospective Cohort study\n","studyDesignUnformatted":"Cross-sectional, Prospective Cohort study","timeCreated":1596407986000,"hasSubmittedData":false,"id":"recCyrPHPWxV5rmzT"},{"shouldShowContactButton":true,"study":"SIGMA","investigator":"Teresa Tusie, Carlos Aguilar, Alfredo Ponce de León, José Sifuentes Osornio","affiliation":"UNAM","country":"Mexico","city":"Mexico City","retrospective":true,"prospective":true,"retrospectiveSampleSize":500,"prospectiveSampleSize":2500,"genotyping":true,"wes":true,"assaysPlanned":["Antibody profiling","Immune profiling"],"otherAssays":"A large repository of biological samples (blood, serum) and DNA is in progress. We expect to have data regarding viral sequencing.\n","researchQuestion":"Are genetic risk factors associated to SARS-CoV-2 infection, disease susceptibility and disease severity?\n","studyDesign":"Cases: individuals with COVID-19+ RT-PCR test or the presence of specific SARS-CoV-2 antibodies. \nControls individuals without respiratory symptoms and negative for the presence of specific SARS-CoV-2 antibodies. \nCox models will be used adjusted for age, gender and ancestry.\nLinear regression models will be use to analyzed the INCMNSZ-Hwo-COVID-19 cohort described below.\n","studyDesignUnformatted":"Cases: individuals with COVID-19+ RT-PCR test or the presence of specific SARS-CoV-2 antibodies. \nControls individuals without respiratory symptoms and negative for the presence of specific SARS-CoV-2 antibodies. \nCox models will be used adjusted for age, gender and ancestry.\nLinear regression models will be use to analyzed the INCMNSZ-Hwo-COVID-19 cohort described below.","timeCreated":1596672691000,"hasSubmittedData":false,"id":"recebeV3xoIEg6Io3"},{"shouldShowContactButton":true,"study":"FHoGID","investigator":"Pierre-Yves Bochud, Carlo Rivolta","affiliation":"University Hospital Lausanne","country":"Switzerland","city":"Lausanne","prospective":true,"prospectiveSampleSize":500,"genotyping":true,"researchQuestion":"To perform a GWAS/contribute to larger GWAS and detect SNPs associated with susceptibilty to COVID-19 and severe COVID-19.\n","studyDesign":"GWAS of susceptibility to COVID / severe COVID-19, using samples for microbiologically documented infection and either healthy controls or seropositive controls (with asymptomatic or pauci-symptomatic infection with SARS-Cov-2.\n","studyDesignUnformatted":"GWAS of susceptibility to COVID / severe COVID-19, using samples for microbiologically documented infection and either healthy controls or seropositive controls (with asymptomatic or pauci-symptomatic infection with SARS-Cov-2.","timeCreated":1597846891000,"hasSubmittedData":true,"id":"reczVN4r0ppdOEKlW"},{"shouldShowContactButton":true,"study":"Michigan Genomics Initiative","investigator":"Sebastian Zöllner, Brooke Wolford, Andy Beck, Kevin Liao, Jiongming Wang, Pedro Orozco del  Pino","affiliation":"University  of Michigan","country":"United States","city":"Ann Arbor","retrospective":true,"prospective":true,"retrospectiveSampleSize":150,"prospectiveSampleSize":120,"genotyping":true,"researchQuestion":"We don't presently have a Covid-related research question other than contributing to the meta-analysis.\n","studyDesign":"The retrospective sample constitutes  the genotyped individuals in the  Biobank of the University of Michigan that either self-identified as being Covid-positive or that have been diagnosed in the Michigan health system.  \n\nThe prospective sample represents us prioritizing individuals from the same recourse that are Covid-positive for genotyping, not an actual prospective study design.\n","studyDesignUnformatted":"The retrospective sample constitutes  the genotyped individuals in the  Biobank of the University of Michigan that either self-identified as being Covid-positive or that have been diagnosed in the Michigan health system.  \n\nThe prospective sample represents us prioritizing individuals from the same recourse that are Covid-positive for genotyping, not an actual prospective study design.","timeCreated":1598540993000,"hasSubmittedData":true,"id":"recKGCYHRXJbArtLF"},{"shouldShowContactButton":true,"study":"VA Million Veteran Program","investigator":"MVP HGI Contact: Jennifer Huffman;  MVP PIs: J Michael Gaziano, Christopher O'Donnell, Philip Tsao","affiliation":"VA Boston Healthcare System, Department of Veterans Affairs ","country":"United States","city":"Boston","studyLink":"www.mvp.va.gov","retrospective":true,"retrospectiveSampleSize":6000,"genotyping":true,"researchQuestion":"The Million Veteran Program (MVP) is a ground-breaking research program sponsored by the Department of Veterans Affairs Office of Research and Development, one of the nation's leaders in health research. Launched in 2011, MVP aims to use genetic, health, lifestyle, and military background information to understand how genes affect health and illness. A primary goal is to conduct research in underrepresented populations, into which a large proportion of Veterans fall. We also aim to study conditions that affect Veterans more frequently than the general population.\n","studyDesign":"Individuals aged 19 to 104 years have been recruited from more than 50 VA Medical Centers nationwide since 2011. Data are being collected from participants using questionnaires, the VA electronic health record (EHR), and a blood sample for genomic and other testing. Each Veteran’s EHR data are being integrated into the MVP biorepository, including inpatient International Classification of Diseases (ICD-9) diagnosis codes, Current Procedural Terminology (CPT) procedure codes, clinical laboratory measurements, and reports of diagnostic imaging modalities. \nDNA extracted from whole blood was genotyped using a customized Affymetrix Axiom biobank array, the MVP 1.0 Genotyping Array. With 723,305 total DNA sequence variants, the array is enriched for both common and rare variants of clinical significance in different ethnic backgrounds.\nSee PMID: 26441289 & 32243820 for more details\n","studyDesignUnformatted":"Individuals aged 19 to 104 years have been recruited from more than 50 VA Medical Centers nationwide since 2011. Data are being collected from participants using questionnaires, the VA electronic health record (EHR), and a blood sample for genomic and other testing. Each Veteran’s EHR data are being integrated into the MVP biorepository, including inpatient International Classification of Diseases (ICD-9) diagnosis codes, Current Procedural Terminology (CPT) procedure codes, clinical laboratory measurements, and reports of diagnostic imaging modalities. \nDNA extracted from whole blood was genotyped using a customized Affymetrix Axiom biobank array, the MVP 1.0 Genotyping Array. With 723,305 total DNA sequence variants, the array is enriched for both common and rare variants of clinical significance in different ethnic backgrounds.\nSee PMID: 26441289 & 32243820 for more details","timeCreated":1599842366000,"hasSubmittedData":true,"id":"recavLEaxRQlbldmL"},{"shouldShowContactButton":true,"study":"GeneRISK","investigator":"Samuli Ripatti, Elisabeth Widén","affiliation":"FIMM","country":"Finland","city":"Helsinki","retrospective":true,"prospective":true,"genotyping":true,"assaysPlanned":["Metabolomics","Antibody profiling"],"researchQuestion":"CVD genetics\n","studyDesign":"population-based prospective cohort of middle aged individuals\n","studyDesignUnformatted":"population-based prospective cohort of middle aged individuals","timeCreated":1600163688000,"hasSubmittedData":true,"id":"recAaxLRAcTGW0g3K"},{"shouldShowContactButton":true,"study":"23andMe","investigator":"Janie F. Shelton, Anjali J. Shastri, Chelsea Ye, Catherine H. Weldon, Teresa Filshtein-Somnez, Daniella Coker, Antony Symons, Jorge Esparza-Gordillo, The 23andMe COVID-19 Team, Stella Aslibekyan, Adam Auton","affiliation":"23andMe","country":"United States","city":"Sunnyvale","studyLink":"https://www.medrxiv.org/content/10.1101/2020.09.04.20188318v1.article-metrics","retrospective":true,"retrospectiveSampleSize":1050000,"genotyping":true,"researchQuestion":"Understanding the host genetic risk factors that influence COVID-19 susceptibility and severity. \n","studyDesign":"Large-scale online survey data collection combined with existing genotyping data for genome-wide association studies.\n","studyDesignUnformatted":"Large-scale online survey data collection combined with existing genotyping data for genome-wide association studies.","timeCreated":1601654091000,"hasSubmittedData":true,"id":"recej4NrH2XipR0uR"},{"shouldShowContactButton":true,"study":"Genome-wide assessment of the gene variants associated with severe COVID-19 phenotype in Iran","investigator":"Ahmadreza Niavarani","affiliation":"Digestive Disease Research Institute (DDRI), Tehran University of Medical Sciences","country":"Iran","city":"Tehran","prospective":true,"prospectiveSampleSize":500,"wes":true,"assaysPlanned":["Transcriptomics","Antibody profiling"],"otherAssays":"\n","researchQuestion":"What are the genetic factors predisposing to the severe COVID-19 phenotype in Iran?\n\n","studyDesign":"As a research institute which has been involved in COVID-19 projects since the beginning of the pandemics, we are going to conduct a study in order to investigate those genetic factors implicated in COVID-19 critical phenotype. We would enroll 500 medical staff with two different clinical phenotypes: a) a group who have never contracted COVID-19 despite of long exposure or have recovered on an outpatient setting; and b) another group of cases who have required intensive care or have died of COVID-19, if any. Those eligible people between 20 to 55 years old would be included. \n","studyDesignUnformatted":"As a research institute which has been involved in COVID-19 projects since the beginning of the pandemics, we are going to conduct a study in order to investigate those genetic factors implicated in COVID-19 critical phenotype. We would enroll 500 medical staff with two different clinical phenotypes: a) a group who have never contracted COVID-19 despite of long exposure or have recovered on an outpatient setting; and b) another group of cases who have required intensive care or have died of COVID-19, if any. Those eligible people between 20 to 55 years old would be included. ","timeCreated":1601972372000,"hasSubmittedData":true,"id":"rec9ymqbp2QJqq30L"},{"shouldShowContactButton":true,"study":"GenOMICC","investigator":"David Maslove","affiliation":"Queen's University","country":"Canada","city":"Kingston","studyLink":"https://genomicc.org/canada/","prospective":true,"prospectiveSampleSize":1000,"wgs":true,"researchQuestion":"What are the genetic determinants of severe, life-threatening COVID-19 infection?\n","studyDesign":"Patients with severe COVID-19 requiring ICU admission will be recruited. A single sample of whole blood will be collected and used for whole genome sequencing. Initial comparison group will be healthy controls, with comparisons to milder disease carried out according to data availability. This is the Canadian arm of the broader GenOMICC research program led by Dr. Kenneth Baillie (Edinburgh), and all study protocols will be harmonized with this effort. \n","studyDesignUnformatted":"Patients with severe COVID-19 requiring ICU admission will be recruited. A single sample of whole blood will be collected and used for whole genome sequencing. Initial comparison group will be healthy controls, with comparisons to milder disease carried out according to data availability. This is the Canadian arm of the broader GenOMICC research program led by Dr. Kenneth Baillie (Edinburgh), and all study protocols will be harmonized with this effort. ","timeCreated":1602004021000,"hasSubmittedData":true,"id":"recsC297mmgOhwscS"},{"shouldShowContactButton":true,"study":"Mount Sinai Health System COVID-19 Genomics Initiative (MSHS-CGI)","investigator":"Joseph Buxbaum,Eimear Kenny,Judy Cho,Noura Abul-husn,Robert Sebra,Yuval Itan,Alexander Charney,Noam Bechmann,Shea Andrews,Laura Sloofman,Kumar Chaudhary,Stuart Sealfon","affiliation":"Mount Sinai ","country":"United States","city":"New York","retrospective":true,"prospective":true,"retrospectiveSampleSize":500,"prospectiveSampleSize":1000,"genotyping":true,"wes":true,"wgs":true,"researchQuestion":"We are examining the genetics of COVID-19 susceptibility. In addition to using genetic data from Mount Sinai Hospital, we are actively COVID-19+ individuals living in NYC, who may have no/reduced access to healthcare.   \n","studyDesign":"We are submitting GWAS sumstats, along with other analyses, using data merged from two sources:\n1\\. \tBio_Me_ Biobank: EHR-linked clinical care cohort with diverse population.\n2\\. \tSeaver Center: Led Study recruiting COVID-19 positive individuals from communities within NYC and New Jersey  \n\nCOVID-19 positive phenotypes and controls were defined using the Phenotype Definitions in the COVID19-HGI analysis plan. \n","studyDesignUnformatted":"We are submitting GWAS sumstats, along with other analyses, using data merged from two sources:\n1. \tBioMe Biobank: EHR-linked clinical care cohort with diverse population.\n2. \tSeaver Center: Led Study recruiting COVID-19 positive individuals from communities within NYC and New Jersey  \n\nCOVID-19 positive phenotypes and controls were defined using the Phenotype Definitions in the COVID19-HGI analysis plan. ","timeCreated":1603313951000,"hasSubmittedData":true,"id":"reclyTThkUL98Il6M"},{"shouldShowContactButton":true,"study":"Egypt hgCOVID hub","investigator":"Yasser M. El-Sherbiny, Ali Sobh, Madonna El-Toukhy, Mohamed Attia, Mohamed Hantera, Doaa Shahin, Tamer El-Hadidy, Mohamed Abdelghafar, Mohamed El-Shanshory, Amr Yassen, Kathrin Aprile von Hohenstaufen Puoti, Kamal Okasha","affiliation":"NOTTINGHAM TRENT UNIVERSITY, Mansoura University, Tanta University","country":"Egypt","city":"Mansoura, Tanta","prospective":true,"prospectiveSampleSize":500,"wes":true,"assaysPlanned":["Transcriptomics","Proteomics","Metabolomics","Immune profiling"],"researchQuestion":"The aim is to understand genetic susceptibility to COVID-19 in Egypt and its interaction with the virus and to provide a better understanding of the biological mechanism leading to severe COVID-19 and to build a longitudinal analysis for severity to increase our ability to predict the severity outcome of the disease\n\n","studyDesign":"The collection will include participants from multiple ongoing prospective studies in Egypt recruiting both COVID cases and control cases. Prospective samples of COVID-19 patients will be collected from Mansoura University hospitals and Tanat University hospitals at dual based hub studies. Studies aim at the identification of host-defined genetic variants contributing to the development of severe COVID-19 disease versus control. Other studies compare longitudinal transcriptomics of mild, moderate to severe patients and the development of asymptomatic silent carrier state in SARS-CoV-2 PCR confirmed participants.\n","studyDesignUnformatted":"The collection will include participants from multiple ongoing prospective studies in Egypt recruiting both COVID cases and control cases. Prospective samples of COVID-19 patients will be collected from Mansoura University hospitals and Tanat University hospitals at dual based hub studies. Studies aim at the identification of host-defined genetic variants contributing to the development of severe COVID-19 disease versus control. Other studies compare longitudinal transcriptomics of mild, moderate to severe patients and the development of asymptomatic silent carrier state in SARS-CoV-2 PCR confirmed participants.","timeCreated":1605746095000,"hasSubmittedData":true,"id":"recg8R0itksLWPVf8"},{"shouldShowContactButton":true,"study":"GENCOV - Implementation of serological and molecular tools to inform COVID-19 patient management","investigator":"Jennifer Taher, Saranya Arnoldo, Yvonne Bombard, Bjug Borgundvaag, Howard Chertkow, Luke Devine, Hanna Faghfoury, Steven Friedman, Anne-Claude Gingras, Vathany Kulasingam, Tony Mazzulli, Allison McGeer, Shelley McLeod, Trevor Pugh, David Richardson, Jared Simpson, Lisa Strug, Ahmed Taher, Jordan Lerner-Ellis","affiliation":"University of Toronto","country":"Canada","city":"Toronto","prospective":true,"prospectiveSampleSize":2000,"wgs":true,"assaysPlanned":["Viral sequencing","Antibody profiling","Immune profiling","Proteomics","Metabolomics"],"otherAssays":"T/B-cell receptor sequencing\n","researchQuestion":"**Aim 1: **Identify the characteristics of the antibody response that result in maintained immune response and better patient outcomes.\n**Aim 2: **Determine impact of genetic differences on COVID-19 infection severity and immune response (including host genome sequencing and T/B-cell receptor sequencing). \n**Aim 3: **Determine impact of different viral strains on antibody response and patient outcomes.\n**Aim 4: **Evaluate the psychological distress of receiving incidental genome sequencing and serology results, as well as the personal utility and impact of receiving these results on risk reduction and other health-related behaviours.\n","studyDesign":"A prospective, observational cohort diagnostic study that combines both laboratory testing and recruitment of SARS-CoV-2 positive in-patients and non-admitted patients from multiple sites including: Sinai Health System (SHS), University Health Network (UHN), Baycrest Health Sciences (including Apotex long-term care home), Mackenzie health and William Osler Health System (WOHS).\nBlood samples will be collected at baseline (if residual blood is available or if patient is in-hospital)), at 1, 6 and 12 months post-COVID-19 diagnosis. Samples will be used for serological testing at all timepoints, biochemistry testing at baseline (or will be sought from the patient chart), genome sequencing at any time point, and T/B-cell receptor sequencing at all timepoints when possible. Nasopharyngeal, oral or nasal swabs will be used to extract viral RNA for viral genome sequencing. \n","studyDesignUnformatted":"A prospective, observational cohort diagnostic study that combines both laboratory testing and recruitment of SARS-CoV-2 positive in-patients and non-admitted patients from multiple sites including: Sinai Health System (SHS), University Health Network (UHN), Baycrest Health Sciences (including Apotex long-term care home), Mackenzie health and William Osler Health System (WOHS).\nBlood samples will be collected at baseline (if residual blood is available or if patient is in-hospital)), at 1, 6 and 12 months post-COVID-19 diagnosis. Samples will be used for serological testing at all timepoints, biochemistry testing at baseline (or will be sought from the patient chart), genome sequencing at any time point, and T/B-cell receptor sequencing at all timepoints when possible. Nasopharyngeal, oral or nasal swabs will be used to extract viral RNA for viral genome sequencing. ","timeCreated":1607999543000,"hasSubmittedData":false,"id":"reclGyJeieoqTU2bM"},{"shouldShowContactButton":true,"study":"Val Gardena","investigator":"Christian Fuchsberger, Cristian Pattaro","affiliation":"Eurac Research","country":"Italy","city":"Bolzano","retrospective":true,"retrospectiveSampleSize":910,"genotyping":true,"wgs":true,"assaysPlanned":["Antibody profiling"],"researchQuestion":"  \n","studyDesign":"Population based study\n","studyDesignUnformatted":"Population based study","timeCreated":1608636389000,"hasSubmittedData":true,"id":"recGvx7T9XjHOHjN6"},{"shouldShowContactButton":true,"study":"CCPM","investigator":"Kathleen C Barnes, Christopher R Gignoux, Michelle Daya, Jonathan Shortt","affiliation":"University of Colorado, Anschutz medical campus","country":"United States","city":"Aurora","studyLink":"https://www.cobiobank.org","retrospective":true,"retrospectiveSampleSize":327,"genotyping":true,"researchQuestion":"GWAS of susceptibility to COVID-19, and COVID-19 severity\n","studyDesign":"The Colorado Center for Personalized Medicine have recruited patients 18 years and older from the UC Health system into their biobank. De-identified data has been extracted from UC Health electronic health records (EHR) for this study. EHR data was used to identify patients who tested positive for COVID 19 and were hospitalized for COVID 19. To date, we have genotyped ~33K patients enrolled in the Biobank on the MEGA array, and imputed these data to the TOPMed reference panel (R2) on the Michigan imputation server.\n","studyDesignUnformatted":"The Colorado Center for Personalized Medicine have recruited patients 18 years and older from the UC Health system into their biobank. De-identified data has been extracted from UC Health electronic health records (EHR) for this study. EHR data was used to identify patients who tested positive for COVID 19 and were hospitalized for COVID 19. To date, we have genotyped ~33K patients enrolled in the Biobank on the MEGA array, and imputed these data to the TOPMed reference panel (R2) on the Michigan imputation server.","timeCreated":1608658230000,"hasSubmittedData":true,"id":"recRVsJcnawwf94Xd"},{"shouldShowContactButton":true,"study":"Genes for Good","investigator":"Albert Vernon Smith, Andrew P Boughton, Kevin W Li","affiliation":"University of Michigan","country":"United States","city":"Ann Arbor","studyLink":"https://genesforgood.org","retrospective":true,"retrospectiveSampleSize":180,"genotyping":true,"researchQuestion":"Genes for Good is a research study aimed at generating and analyzing an enormous database of health and genetic information. This research will provide valuable biological insight into the causes of common diseases. \n","studyDesign":"Population based study that has recruited individuals via word-of-mouth on Facebook. Individuals answer surveys with respect to demographics, health history, and other tracking information: For Covid19, Genes for good sent questionaires on Covid19 status, including testing and symptoms. To date, surveys have been sent in April 2020 and October 2020. We have received answers from close to 5,000 individuals that have also been genotyped. It is anticipated that further rounds of surveying will occur in 2021.\n","studyDesignUnformatted":"Population based study that has recruited individuals via word-of-mouth on Facebook. Individuals answer surveys with respect to demographics, health history, and other tracking information: For Covid19, Genes for good sent questionaires on Covid19 status, including testing and symptoms. To date, surveys have been sent in April 2020 and October 2020. We have received answers from close to 5,000 individuals that have also been genotyped. It is anticipated that further rounds of surveying will occur in 2021.","timeCreated":1608664715000,"hasSubmittedData":true,"id":"recYXcXP7OXzP9m4B"},{"shouldShowContactButton":true,"study":"CCHC COVID-19 GAWS","investigator":"Jennifer Below, Douglas Shaw, Hannah Polikowski, Lauren Petty, Hung-hsin Chen","affiliation":"Vanderbilt University","country":"United States","city":"Nashville","genotyping":true,"otherAssays":"\n","researchQuestion":"Identify common genetic variants associated with COVID-19 susceptibility in a Mexican-American cohort through genome-wide association analysis.\n","studyDesign":"46 COVID positive patients and 3235 control patients were selected from a Mexican American cohort from Cameron county, TX for genome-wide association. Association analysis run through SAIGE software (GLMM) with age, sex, age\\*age, sex\\*age, sex\\*sex, and PCs 1-20 as identified through principal component analysis. \n","studyDesignUnformatted":"46 COVID positive patients and 3235 control patients were selected from a Mexican American cohort from Cameron county, TX for genome-wide association. Association analysis run through SAIGE software (GLMM) with age, sex, age*age, sex*age, sex*sex, and PCs 1-20 as identified through principal component analysis. ","timeCreated":1609800856000,"hasSubmittedData":true,"id":"recQCwRkJi4Hpdoyw"},{"shouldShowContactButton":true,"study":"TwinsUK","investigator":"Massimo Mangino, Emma Duncan, Tim Spector","affiliation":"King's College London, Department of Twin Research","country":"United Kingdom","city":"London","studyLink":"https://twinsuk.ac.uk/","retrospective":true,"retrospectiveSampleSize":5100,"genotyping":true,"wgs":true,"assaysPlanned":["Immune profiling","Transcriptomics","Proteomics","Metabolomics","Antibody profiling"],"otherAssays":"We have currently available a range of different OMICS platform (Metabolomics, trascriptomics, microbiome, glcomics, immune profile). We are in the process to expand the genotype to the whole cohort.\n","researchQuestion":"We are currently working on a number of different OMICs studies to understand the biology of COVID-19 and the body’s response, as well as the physical and mental health implications of social changes and self-isolation due to COVID-19.\n","studyDesign":"TwinsUK was set in 1992 to investigate the incidence of osteoporosis and other rheumatologic diseases in identical twins. To date, we collected information’s on over 15,000 identical and non-identical twins from across the UK, with ages ranging from 18 to 100. TwinsUK main aim is to investigate the genetic and environmental basis of a range of complex diseases and conditions. Current research includes the genetics of metabolic syndrome, cardiovascular disease, the musculoskeletal system, ageing, sight as well as how the microbiome affects human health.\n","studyDesignUnformatted":"TwinsUK was set in 1992 to investigate the incidence of osteoporosis and other rheumatologic diseases in identical twins. To date, we collected information’s on over 15,000 identical and non-identical twins from across the UK, with ages ranging from 18 to 100. TwinsUK main aim is to investigate the genetic and environmental basis of a range of complex diseases and conditions. Current research includes the genetics of metabolic syndrome, cardiovascular disease, the musculoskeletal system, ageing, sight as well as how the microbiome affects human health.","timeCreated":1610812437000,"hasSubmittedData":true,"id":"recbmlu2i3aPm82nI"},{"shouldShowContactButton":true,"study":"Danish COVID-19 genomic consortium","investigator":"Frank Geller","affiliation":"Statens Serum Institut","country":"Denmark","city":"Copenhagen","retrospective":true,"prospective":true,"retrospectiveSampleSize":15000,"prospectiveSampleSize":5000,"genotyping":true,"assaysPlanned":["Viral sequencing"],"otherAssays":"part of the cohort will have virus sequences\n","researchQuestion":"National consortium of key players in the clinical management of COVID-19 and biomedical researchers to establish a genetic cohort of COVID-19 patients to study host-related molecular factors important for disease etiology and severity.\n","studyDesign":"ca. 15,000 cases identified from existing biobanks\nca. 5,000 extra cases to be genotyped\n","studyDesignUnformatted":"ca. 15,000 cases identified from existing biobanks\nca. 5,000 extra cases to be genotyped","timeCreated":1612200822000,"hasSubmittedData":false,"id":"rec7m1X7KqwLLn9Gg"},{"shouldShowContactButton":true,"study":"BeLCovid","investigator":"Isabelle Migeotte, Souad Rahmouni","affiliation":"Hôpital Erasme, Université Libre de Bruxelles, Fonds Erasme and Université de Liège, CHU of Liège, CHC MontLégia","country":"Belgium","city":"Bruxelles, Liège","prospective":true,"prospectiveSampleSize":1000,"genotyping":true,"researchQuestion":"Search for genetic determinants of COVID-19 susceptibility, severity and outcome through GWAS analysis of SARS-CoV2 infected patients, within the frame of the COVID-19 host genetics initiative.\n","studyDesign":"Recruited individuals are SARS-CoV2 PCR positive and either hospitalised patients in Hôpital Erasme (Brussels), Centre Hospitalier Universitaire of Liège, and CHC-MontLégia between March and December 2020, or asymptomatic hospital staff members. DNA samples and corresponding demographic and clinical data are sent to Finland Institute for Molecular Medicine where genotyping is performed. Protocols were approved by ethic committees of Erasme and Liege University Hospitals.\n","studyDesignUnformatted":"Recruited individuals are SARS-CoV2 PCR positive and either hospitalised patients in Hôpital Erasme (Brussels), Centre Hospitalier Universitaire of Liège, and CHC-MontLégia between March and December 2020, or asymptomatic hospital staff members. DNA samples and corresponding demographic and clinical data are sent to Finland Institute for Molecular Medicine where genotyping is performed. Protocols were approved by ethic committees of Erasme and Liege University Hospitals.","timeCreated":1612438207000,"mapLocation":"Liège, Belgium","hasSubmittedData":true,"id":"recyQX2cXRqRZapzt"},{"shouldShowContactButton":true,"study":"Vanda COVID","investigator":"Sandra Smieszek, Mihael Polymeropoulos, Bart Przychodzen, Christos Polymeropoulos, Vasilios Polymeropoulos","affiliation":"Vanda Pharmaceuticals Inc.","country":"United States","city":"Washington DC","wgs":true,"researchQuestion":"hospitlized severe GWAS\n","studyDesign":"2 clinical trials of hospitlized patients CALYPSO and ODYSSEY\n","studyDesignUnformatted":"2 clinical trials of hospitlized patients CALYPSO and ODYSSEY","timeCreated":1612965697000,"hasSubmittedData":true,"id":"recoNnhW6AbKYnco1"},{"shouldShowContactButton":true,"study":"Host genetic factors for COVID-19 severity and outcome in western Indian population","investigator":"Chaitanya G Joshi","affiliation":"Gujarat Biotechnology Research Centre (GBRC)","country":"India","city":"Gandhinagar","retrospective":true,"retrospectiveSampleSize":571,"genotyping":true,"assaysPlanned":["Viral sequencing","Transcriptomics"],"researchQuestion":"Host genetic factors contributing to the SARS-CoV-2 susceptibility and severity need to be studied in detail. Therefore, the aim of our study was to evaluate host factors in susceptibility and survival in COVID-19 during recent pandemic in Gujarat, India.\n","studyDesign":"Patients (n=571) with asymptomatic to severe infection were enrolled in the study with monitoring of their outcome as recovered or deceased. For genotyping, we used Axiom™ Precision Medicine Diversity Array (PMDA) Plus Kit, 96-format containing 8,68,298 markers selected for high genomic coverage (Thermo Fisher Scientific) on GeneTitan Multi-Channel (MC) Instrument (Thermo Fisher Scientific). Data was further analysed using three different GWAS tools (PLINK OrdinalGWAS. Jl and SAIGE) to correlate the association of host genetic variants.\n","studyDesignUnformatted":"Patients (n=571) with asymptomatic to severe infection were enrolled in the study with monitoring of their outcome as recovered or deceased. For genotyping, we used Axiom™ Precision Medicine Diversity Array (PMDA) Plus Kit, 96-format containing 8,68,298 markers selected for high genomic coverage (Thermo Fisher Scientific) on GeneTitan Multi-Channel (MC) Instrument (Thermo Fisher Scientific). Data was further analysed using three different GWAS tools (PLINK OrdinalGWAS. Jl and SAIGE) to correlate the association of host genetic variants.","timeCreated":1613543496000,"hasSubmittedData":true,"id":"recCkR0RYggTibwgA"},{"shouldShowContactButton":true,"study":"Genetics of COVID-19 in Children and Young Adults in the UAE","investigator":"Ahmad Abou Tayoun, Sathishkumar Ramaswamy","affiliation":"Al Jalila Childrens Specialty Hospital","country":"United Arab Emirates","city":"Dubai","prospective":true,"prospectiveSampleSize":250,"wes":true,"assaysPlanned":["Viral sequencing","Transcriptomics"],"researchQuestion":"Are genetic variants associated with coronavirus disease 2019 (COVID-19) in children and young adult patients?\n","studyDesign":"The study design will be divided into 4 discrete steps that include: (1) Recruitment of covid positive children and young adult patients (2) Obtaining thorough medical information; (3) Exome wide sequencing  (4) Data analysis and novel gene prioritization;\n","studyDesignUnformatted":"The study design will be divided into 4 discrete steps that include: (1) Recruitment of covid positive children and young adult patients (2) Obtaining thorough medical information; (3) Exome wide sequencing  (4) Data analysis and novel gene prioritization;","timeCreated":1613891916000,"hasSubmittedData":false,"id":"recGNGD9U7oNKRgNh"},{"shouldShowContactButton":true,"study":"Genetic factors in the course of SARS-CoV-2 infection: epidemiologic investigation on peptide signatures, immunity, genetic predisposition, and alterations in SARS-CoV-2 (EPI-Dx)","investigator":"Dr. Karsten Rainer Heidtke","affiliation":"ATLAS Biolabs GmbH","country":"Germany","city":"Berlin","prospective":true,"prospectiveSampleSize":500,"genotyping":true,"wes":true,"assaysPlanned":["Viral sequencing","Proteomics"],"researchQuestion":"Harmless, serious or even fatal: Which role do genetic factors play in the course of infection with SARS-CoV-2?\n","studyDesign":"During the EPI-Dx study, various clinical and molecular genetic parameters of 500 individuals will be examined. The particular research interest is on the membrane proteins ACE2 and TMPRSS2. Since the genetic makeup varies from person to person, this results in different phenotypic expressions, leading to individual courses of the disease with or without severe complications. Genetic variants of the SARS-CoV-2 virus are also taken into account. The EPI-Dx study is being conducted by ATLAS Biolabs, in.vent Diagnostica and MicroDiscovery. The project is funded by the German Federal Ministry of Education and Research, grant no. 03COV21.\n","studyDesignUnformatted":"During the EPI-Dx study, various clinical and molecular genetic parameters of 500 individuals will be examined. The particular research interest is on the membrane proteins ACE2 and TMPRSS2. Since the genetic makeup varies from person to person, this results in different phenotypic expressions, leading to individual courses of the disease with or without severe complications. Genetic variants of the SARS-CoV-2 virus are also taken into account. The EPI-Dx study is being conducted by ATLAS Biolabs, in.vent Diagnostica and MicroDiscovery. The project is funded by the German Federal Ministry of Education and Research, grant no. 03COV21.","timeCreated":1616767442000,"hasSubmittedData":false,"id":"recQbSyQTGO1KZoLR"},{"shouldShowContactButton":true,"study":"CHOP_CAG","investigator":"Joseph Glessner, Hakon Hakonarson, Xiao Chang","affiliation":"Children's Hospital of Philadelphia","country":"United States","city":"Philadelphia","genotyping":true,"researchQuestion":"What can we reveal about host genetics that predisposes or protects certain individuals from becoming COVID infected, possibly escalating to hospitalization, vs. remaining healthy?\n","studyDesign":"Illumina SNP genotyping microarray of Hapmap and Global screening array (GSA) type. 339 COVID+ cases vs. 1027 COVID- controls with 256 additional cases and matched controls to be added.\n","studyDesignUnformatted":"Illumina SNP genotyping microarray of Hapmap and Global screening array (GSA) type. 339 COVID+ cases vs. 1027 COVID- controls with 256 additional cases and matched controls to be added.","timeCreated":1618351111000,"hasSubmittedData":true,"id":"recbXCsGzwmsR5Gcp"},{"shouldShowContactButton":true,"study":"EraCORE","investigator":"Carolina Medina-Gomez; Andre G. Uitterlinden; M.Arfan Ikram","affiliation":"Erasmus University Medical Center","country":"Netherlands","city":"ROTTERDAM","prospective":true,"prospectiveSampleSize":1300,"genotyping":true,"assaysPlanned":["Viral sequencing"],"researchQuestion":"What is the natural course of the Covid-19 infection and which are the factors that influence it ?\n","studyDesign":"EraCORE, short for Erasmus MC Covid-19 Observational Research, collects and streamlines all information from Erasmus MC covid patients for research purposes.\nThis means that researchers who want to conduct research into Covid-19 at Erasmus MC will have access to all data collected so far from covid patients, including blood samples, radiological scans and other clinical information. Researchers can analyze this information in an integrated manner.\n","studyDesignUnformatted":"EraCORE, short for Erasmus MC Covid-19 Observational Research, collects and streamlines all information from Erasmus MC covid patients for research purposes.\nThis means that researchers who want to conduct research into Covid-19 at Erasmus MC will have access to all data collected so far from covid patients, including blood samples, radiological scans and other clinical information. Researchers can analyze this information in an integrated manner.","timeCreated":1620301193000,"hasSubmittedData":true,"id":"recp0ug3vNipqAzvC"},{"shouldShowContactButton":true,"study":"Women's Genome Health Study (WGHS), i.e. the genomics subset of Women's Health Study (WHS)","investigator":"Daniel I. Chasman, Franco Giulianini, Paul M Ridker, Julie E. Buring","affiliation":"Brigham and Women's Hospital","country":"USA","city":"Boston","studyLink":"https://whs.bwh.harvard.edu","researchQuestion":"To detect common variant genetic associations across the genome with overall COVID-19 status (yes/no) from approximately March-December 2020 in a population sample of older women of European ancestry.\n\n","studyDesign":"The WGHS/WHS includes female healthcare professionals recruited with age >45 years (median 54) in 1992-94 with ongoing observational follow-up.  Whole genome genetic data exist in the WGHS substudy with verified European ancestry.  In 2020, participants were asked by questionnaire about COVID-19 status (yes/no), a composite outcome of \"hospitalized for COVID-19\", \"diagnosed with COVID-19\", or \"positive test for COVID-19\".  The submitted genome-wide summary statistics correspond to Analysis\\_C2\\_v2. \n","studyDesignUnformatted":"The WGHS/WHS includes female healthcare professionals recruited with age >45 years (median 54) in 1992-94 with ongoing observational follow-up.  Whole genome genetic data exist in the WGHS substudy with verified European ancestry.  In 2020, participants were asked by questionnaire about COVID-19 status (yes/no), a composite outcome of \"hospitalized for COVID-19\", \"diagnosed with COVID-19\", or \"positive test for COVID-19\".  The submitted genome-wide summary statistics correspond to Analysis_C2_v2. ","timeCreated":1620932882000,"hasSubmittedData":true,"id":"recILSX5qlipKHh6e"},{"shouldShowContactButton":true,"study":"STOP-Coronavirus, WP3-Host genetics","investigator":"Carmen Ayuso, Berta Almoguera, Marta Cortón, Rosario López, Pablo Mínguez, Lorena Ondo, Andrea Martínez Ramas, Lidia Fernández Caballero, Marta del Pozo, Sandra Zazo, Lucía Llanos, Antonio Herrero, Ignacio Mahillo, Encarna Guillén Navarro, María Elena Pérez Tomás, María Barreda Sánchez, F. Javier Ruiz Hornillos, Estela Paz Artal, Esther Mancebo, Stop_Coronavirus S. Group","affiliation":"Health Research Institute Fundación Jiménez Díaz (IIS-FJD), Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA), Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12)","country":"Spain","city":"Madrid, Murcia","prospective":true,"prospectiveSampleSize":3000,"genotyping":true,"wes":true,"researchQuestion":"The study aims to identify genetic biomarkers of the host associated to COVID-19 progression.\n","studyDesign":"\\- DNA extracted from blood samples of patients with confirmed COVID-19 and signed informed consent from four spanish hospitales (HU-FJD, HUIE, H12O and HCUVA).\n\\- Clinical history is extracted and standardized for all patients.\n\\- The severity of COVID-19 is established for each patient based on symptoms.\n\\- Genotyping is performed over ~665.000 SNPs\n\\- GWAS analysis in severity groups\n","studyDesignUnformatted":"- DNA extracted from blood samples of patients with confirmed COVID-19 and signed informed consent from four spanish hospitales (HU-FJD, HUIE, H12O and HCUVA).\n- Clinical history is extracted and standardized for all patients.\n- The severity of COVID-19 is established for each patient based on symptoms.\n- Genotyping is performed over ~665.000 SNPs\n- GWAS analysis in severity groups","timeCreated":1626700038000,"mapLocation":"Madrid, Spain","hasSubmittedData":false,"id":"recAq8NbFUhddH9Kn"},{"shouldShowContactButton":true,"study":"CGEn HostSeq - Canadian COVID-19 Human Host Genome Sequencing Databank","investigator":"Lisa Strug, Jennifer Brooks, Shelley Bull, Lloyd Elliott, France Gagnon, Celia Greenwood, Rayjean Hung, Jerry Lawless, Andrew Paterson, Lei Sun, Elika Garg, Anat Halevy, Samantha Yoo, Naveed Aziz, Steven Jones, Bartha Knoppers, Mark Lathrop, Stephen Scherer, Stuart Turvey, Rae Yeung, Upton Allen, Angela Cheung, David Maslove, Jordan Lerner-Ellis, Rulan Parekh, Catherine Biggs, Juthaporn Cowan, Francine Ducharme, Mario Ostrowski","affiliation":"The Hospital for Sick Children/University of Toronto, University of Toronto, University of Toronto/Mount Sinai Hospital, Simon Fraser University, University of Toronto, McGill University, University of Toronto/Mount Sinai Hospital, University of Waterloo, The Hospital for Sick Children/University of Toronto, University of Toronto, Simon Fraser University, The Hospital for Sick Children, The Hospital for Sick Children, The Hospital for Sick Children, University of British Columbia, McGill University, McGill University, The Hospital for Sick Children, BC Children's Hospital, The Hospital for Sick Children, The Hospital for Sick Children, University Health Network, Queens University, Mount Sinai Hospital, Women's College Hospital, BC Children's Hospital, The Ottawa Hospital, University of Montreal/Ste-Justine University Health Centre, St. Michael's Hospital","country":"Canada","city":"Toronto ","prospective":true,"prospectiveSampleSize":10000,"wgs":true,"assaysPlanned":["Viral sequencing"],"researchQuestion":"**Primary:** The HostSeq program is a databank of Genome Sequence and clinical information to support COVID-19 research across Canada, prepare the country for research in future pandemics and create infrastructure for research into other diseases.\n**Secondary:** Identifiable rare, common and/or structural variation affecting genes mediating the host’s responses to COVID-19 influence: \ni) Susceptibility to acquisition of COVID-19; \nii) Risk of the most severe forms of disease due to the virus. \n**Tertiary:** Genes associated with COVID-19 disease severity and susceptibility will provide therapeutic targets for the development of new or repurposed medicines and will support vaccine development.\n","studyDesign":"The CGEn HostSeq Databank is a pan-Canadian program, composed of REB approved studies on COVID-19 allowing for whole genome sequencing.\nEligible participants are consented through REB approved studies across Canada with approval to perform genome sequencing and have their data participate in future research.\nConsented individuals of any age are eligible to participate with confirmed positive SARS-CoV-2 test or if suspected to be positive due to exposure to a positive case or by clinical investigation to have COVID-19-related symptoms.\n","studyDesignUnformatted":"The CGEn HostSeq Databank is a pan-Canadian program, composed of REB approved studies on COVID-19 allowing for whole genome sequencing.\nEligible participants are consented through REB approved studies across Canada with approval to perform genome sequencing and have their data participate in future research.\nConsented individuals of any age are eligible to participate with confirmed positive SARS-CoV-2 test or if suspected to be positive due to exposure to a positive case or by clinical investigation to have COVID-19-related symptoms.","timeCreated":1632794707000,"hasSubmittedData":false,"id":"recalnSnFm4GMfDvx"},{"shouldShowContactButton":true,"study":"COVID-19 Host Genomics Outcomes Study","investigator":"Lynn Carmichael, Catherine Hajek,David Condon","affiliation":"Sanford Health","country":"United States","city":"Sioux Falls, SD","retrospective":true,"retrospectiveSampleSize":10000,"genotyping":true,"researchQuestion":"We aim to evaluate for genomic predictors of COVID-19 phenotypes. Early evidence has demonstrated various possible genomic targets for predictors of COVID-19 severity [Tanigawa 2020, Kolin 2020,]. Ongoing work from the UK Biobank, the COVID-19 Host Genetics Initiative, the COVID Human Genetic Effort and others are focused on COVID-19 genomic discovery. Our study would not be powered for new discovery; however, we would be able to evaluate whether published genomic findings associate with disease severity or susceptibility in the Sanford Health patient population. Confirming genomic associations with severity has the potential to be useful in the clinical setting in a preemptive manner or during early management.  \n","studyDesign":"For candidate gene and genome-wide case-control association analysis and polygenic risk score development we will follow the protocols established by Zondervan et al [Zondervan 2007, 2009, 2010, 2011] to ensure sufficient quality control, proper marker selection, a large enough set of cases and controls for each analysis, and proper statistical methods for interpreting the data.\nWe will compare genomic data from the positive and negative COVID patient populations as well as between those deemed to be severe vs less severe to assess for differences in frequency of reported risk SNPs. Additional potential targets including _HBB, CFTR, CCR5, APOL1 _and _APOE _[Murray 2020, Kuo 2020]. It has also been hypothesized that there are monogenic conditions such as inherited thrombophilias that predispose to severe COVID-19 \n","studyDesignUnformatted":"For candidate gene and genome-wide case-control association analysis and polygenic risk score development we will follow the protocols established by Zondervan et al [Zondervan 2007, 2009, 2010, 2011] to ensure sufficient quality control, proper marker selection, a large enough set of cases and controls for each analysis, and proper statistical methods for interpreting the data.\nWe will compare genomic data from the positive and negative COVID patient populations as well as between those deemed to be severe vs less severe to assess for differences in frequency of reported risk SNPs. Additional potential targets including HBB, CFTR, CCR5, APOL1 and APOE [Murray 2020, Kuo 2020]. It has also been hypothesized that there are monogenic conditions such as inherited thrombophilias that predispose to severe COVID-19 ","timeCreated":1632854096000,"hasSubmittedData":false,"id":"recsuGGypoB3NXqBg"},{"shouldShowContactButton":true,"study":"MexGen-COVID Initiative","investigator":"Päivi Pajukanta, Bogdan Pasaniuc, Manish J. Butte, Daniel H. Geschwind, Dan Teresa Tusié-Luna, Carlos Aguilar-Salinas","affiliation":"UCLA, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán","country":"United States, Mexico","city":"Los Angeles, Mexico","retrospective":true,"prospective":true,"retrospectiveSampleSize":3500,"prospectiveSampleSize":4500,"genotyping":true,"assaysPlanned":["Antibody profiling"],"researchQuestion":"To investigate whether Mexicans have population specific factors contributing to their high COVID-19 susceptibility.\n","studyDesign":"We will collect genotypic and phenotypic information from COVID-19 infected individuals in the Mexico City metropolitan area including hospitalized and severe patients. Genome-wide association studies will be performed with population-based controls to investigate host genetic factors contributing to high COVID-19 susceptibility among Mexicans.\n","studyDesignUnformatted":"We will collect genotypic and phenotypic information from COVID-19 infected individuals in the Mexico City metropolitan area including hospitalized and severe patients. Genome-wide association studies will be performed with population-based controls to investigate host genetic factors contributing to high COVID-19 susceptibility among Mexicans.","timeCreated":1634860315000,"hasSubmittedData":false,"id":"rec2JWV2WcacTO3Lh"},{"shouldShowContactButton":true,"study":"Polygenic risk score to predict COVID-19 mortality","investigator":"Jasmine Tan","affiliation":"National Taiwan University Hospital","country":"Taiwan","city":"Taipei","retrospective":true,"researchQuestion":"We are doing a PRS project in UK Biobank and have reached AUC 0.8 to predict COVID-19 mortality risk in internal testing data. We are now looking for external validation data and researchers who are interested to join.\n","studyDesign":"\\-\n","studyDesignUnformatted":"-","timeCreated":1635089457000,"hasSubmittedData":false,"id":"recTVXh8pW0Z8K5pf"}]